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ABSTRACT
Chemotherapeutics are used extensively to treat cancer patients and often induce adverse
effects, including taste dysfunctions. Disturbances in taste are detrimental to the overall
well-being of cancer patients, causing malnutrition and weight loss that aggravate their
condition even further. Inflammation due to an infection of the taste sensory system as
previously shown, has detrimental effects on the taste sensation. Our study focused on if
chemotherapy induced an inflammatory response in the taste buds using cyclophosphamide
(CYP), a pro-drug. Once metabolized by the P450 enzyme complex, its primary metabolite
functions as an alkylating agent, involved in inhibiting cell replication cycle and cell death.
We used immunohistochemistry and fluorescent microscopy to analyze and observe the
expression of the pro-inflammatory cytokine TNF-α in different types of taste sensory
cells. Previously we found that a sulfhydryl cytoprotective drug, amifostine, can prevent
taste bud damage and therefore we asked if it could prevent an inflammatory response. Our
research observed an inflammatory response in both Type II and Type III cells in taste buds
of fungiform and circumvallate papilla. Type II cells showed a peak response at 8- and 24hour post-CYP injection whereas Type III cells had a peak expression at 24-hour post-CYP
injection in the circumvallate papillae. Pre-treatment with amifostine appeared to prevent
an inflammatory response within taste buds from CYP induced cytokine response.
Identifying inflammation as a potential factor in taste related disorders could help clinicians
develop better treatment modalities such as cytoprotective drugs preventing chemotherapy
induced long term adverse effects such as malnutrition. In the future, we would like to
expand our research to investigate expression of other pro-inflammatory cytokines and
possible signaling mechanisms that could be responsible for CYP-induced inflammatory
response in Type III cells.
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CHAPTER 1. INTRODUCTION
1.1. Overview
Taste is an important sensory modality found in animals for the main purpose of
identifying food and nutrients before ingestion. In humans, the gustatory system has two
main purposes, it helps to detect and differentiate between nutrients and harmful toxins.
Also, signals from the peripheral gustatory system prepare the gut for proper digestion and
absorption of nutrients by releasing digestive juices and enzymes. Alterations in taste are
common side-effects in patients undergoing chemotherapy (Sánchez-Lara et al., 2010).
Our study involves investigating alterations in the taste system due to cyclophosphamide
(CYP), a chemotherapy drug with alkylating properties, in a mouse model to identify any
inflammatory reaction in both fungiform and circumvallate papillae. We also studied
Amifostine, a sulfhydryl drug, to see if it has any protective effects in ameliorating this
inflammation. This chapter describes the significance of the taste sensory system and the
relationship it has among multiple factors. Subsequent chapters describe the experimental
results of this project in relation to previous research and the future direction of our
experimental results.
1.2 Importance of taste
Like other major sensory systems such as olfaction, taste is an important sensory
system which helps most non-human animals and humans perceive the world around us.
The importance of taste stems from its function of protecting the gastrointestinal system
against ingestion of harmful substances as well as help provide adequate nutrition to the
individual. There are five different basic tastes that animals have been identified and
characterized (sweet, bitter, sour, salty and umami) that perform specific functions
(Chaudhari & Roper, 2010).
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1.2.1 Sweet taste
Sweet taste originates from food containing carbohydrates. Foods judged as sweet
are usually preferred by most organisms. Carbohydrates are naturally present in plants and
are the most important source of energy for organisms. Even though infants do not have
fully developed taste receptors, they readily ingest their mother’s milk which is high in free
sugars and glutamate. Therefore, our predilection towards sugary food could possibly begin
there (Ramirez (1990). Other studies also indicate that carbohydrate is the main source of
energy for a human diet. For example, it is widely known that brain function depends on
a steady and quick source of glucose. Also, ingestion of carbohydrates increases glucose
oxidation. Thus, carbohydrate laden food serves the purpose of providing a ready source
of glucose (Jéquier, 1994).
1.2.2 Umami taste
The amino acid L-glutamate is the principal compound that elicits a unique taste
called umami. Monosodium glutamate (MSG) is the prototypical example of umami,
sometimes referred to as a “savory” taste. In 1908, glutamic acid was first extracted from
seafood by a scientist named Ikeda. He determined that this compound gives a palatable
savory sensation to food and categorized this as a basic taste called umami. MSG is used
more frequently in the eastern part of the world than in the western nations (France Bellisle,
1999). Endogenous glutamate has numerous functions within the body. Being an amino
acid, it is found in many peptides and proteins. Monosodium glutamate is one of the major
amino acids present in food adding natural flavor. It is also an energy source in the body,
involved in glutathione synthesis (Jinap & Hajeb, 2010). Food such as tomatoes and
mushrooms have a distinct umami taste due to the presence of high quantities of glutamate.
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A study conducted by a group in France found that MSG enhanced the palatability of food
(F. Bellisle et al., 1991). While it can improve the palatability of foods, the addition of
MSG in food has been a controversial issue, mainly by blaming glutamate for ill health.
The phenomenon was even termed ‘Chinese restaurant syndrome’ (Kwok, 1968). Years of
study have concluded and refuted any claims of ill-health due to MSG (Kenney, 1986).
1.2.3 Bitter taste
Bitter taste is an important taste modality as it is responsible for protecting the body
against ingestion of harmful chemical substances. Bitter tasting compounds are not just
aversive to humans, but to most other animal species as well, suggesting its importance in
protecting against harm (Chandrashekar et al., 2000). This is quite evident in synthetic
compounds or plant secondary metabolites that are generally harmful to the individual.
1.2.4 Salt taste
Salt taste is generally detected by the presence of sodium chloride and sodium
chloride is implicated in a lot of chronic diseases in humans such as hypertension (Mattes,
1984). It is used as a seasoning in almost all foods to increase its palatability and we have
an inherent need for sodium due to its life sustaining functions (Fitzsimons, 1998). It has
been noted though that there is a difference in how rats and humans ingest sodium chloride.
Humans like it with food and rats like it with fluid (Beauchamp & Bertino, 1985). Unlike
sweet, humans have not been found to have an inherent predilection towards salty taste and
are somewhat indifferent towards salt sensation. Their detection for salt taste stimuli
develops over the first few months post birth, which is correlated with the development of
central taste sensory structures (Beauchamp, Cowart, & Moran, 1986).
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It has been noted that neonates do not specifically differentiate between salt and
water which could be due to the lack of development of salt taste sensory system. This was
corroborated by studies in sheep and rats exhibiting a lack of neural innervation and
amiloride sensitive channels in taste cells. The taste sensation of salt also induces a wide
array of physiologic changes which includes the secretion of saliva, gastric juices, and
pancreatic enzymes that play key roles in metabolic processes within a human being (Hill
& Mistretta, 1990).
1.2.5 Sour taste
Sour taste is an important sensory modality which denotes the presence of acid in
food and is often used to determine whether a food is safe to eat or is rancid and should be
discarded (Chaudhari & Roper, 2010). It is commonly found in nature in the form of acetic
acid, tartaric acid or maleic acid in fruits and berries. Even though they are found
ubiquitously in nature, the intensity and sensory characteristic of these acids differ widely
(Törnwall et al., 2012). A sour substance is often used as an additive to enhance the flavor
and the quality of the food to be ingested. These substances are also often used in baked
goods, beverages and confections as an enhancer (Hartwig, 1995). Apart from this,
acidulants are also used in pH control to prevent any microbial growth. Acidulants also
help in gelling of food and sometimes used as a chelating agent (Johnson & Peterson,
1974). Early studies based on inorganic salts suggested that hydrogen ions were responsible
for sour taste sensation. Later studies found that the sour taste elicited by organic acids was
due to hydrogen ions dissociating from carboxyl groups. Studies performed to investigate
the differences in intensity of different organic and inorganic acids based on molar
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concentrations, suggest the intensity of sour sensation elicited by acids is not solely depend
on molar concentrations (Makhlouf & Blum, 1972).
1.3. General morphology of the taste buds
The taste sensory organ or taste bud is an onion-shaped structure comprised of
about 50~100 differentiated taste cells, referred to as Types I, II, and III, in the taste papillae
on the tongue. These three differentiated taste cells types are responsible for the
transduction of five basic tastes: sweet, bitter, umami, sour and salty. Taste buds are
organized within papillae called fungiform, foliate and circumvallate. Fungiform papillae
are found on the anterior end of tongue. Foliate are located on the lateral sides of the tongue
and circumvallate are found in the center posterior part of the tongue. Taste cells form tight
junctions preventing any permeation of water but allow ions such as Na+ to permeate into
the interstitial spaces, which is one of the ways taste cells detect Na+ (Chaudhari & Roper,
2010).
Taste cells are differentiated polarized cells that have short life spans. They are
known to undergo renewal due to their closeness to the external environment using the
progenitor K14+/K5+ cells (Chandrashekar, Hoon, Ryba, & Zuker, 2006; Okubo, Clark,
& Hogan, 2009). These progenitor cells are in the basal epithelial layer, immediately below
the onion shaped taste buds. Post mitotic cells differentiate to form mature TSCs when
proper signals are induced from the taste bud (Adler et al., 2000; Barlow, 2015). The apical
ends of the mature differentiated taste sensory cell encounter a nutrient through the pore of
the taste bud. When a food molecule encounters receptors in the microvilli of taste sensory
cells, a transduction pathway is activated by the food molecule. Electron micrograph
analysis of different taste buds have shown discrete ultrastructural features such as
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differing electron densities of cytoplasm, thickness of the microvilli, difference in the kind
of receptors on cells (for example, the presence or absence of synapses in cells) or the
difference in thickness of microvilli in cells (Pumplin, Yu, & Smith, 1997). Antibody
labeling of cells identified protein markers either involved in downstream signaling
pathways, receptors or cell structure have been developed to help distinguish individual
cell types from each other. For example, alpha gustducin is involved in the downstream
cell signaling in Type II cells and SNAP25 is a core complex of the SNARE involved in
exocytosis of neurotransmitter vesicles in Type III cells (Yang, Crowley, Rock, &
Kinnamon, 2000). Understanding the differences between the mature cell types is
important for studying the taste system.
1.3.1 Type I taste cells
Type I cells are among the most ubiquitous cells in taste buds and are involved in
salt taste transduction. These cells are spindle shaped, extending all the way from the taste
bud’s basement membrane, with its microvilli projecting from its apical ends close to the
taste bud pore. The cytoplasm of these cells does not have many organelles except for a
distinctive Golgi-apparatus and dense bodies. Based on the cytoplasmic staining properties
due to basophilic dyes, and varying electron density, these cells have been called dark cells.
These cells are known to form tight junctions and the lamellate processes surround the
neighboring cells within the taste bud like a glial cell (Farbman, Albert I. 1965). These
cells are widely found within the taste bud with a population equivalent to 40% of the entire
population (Finger, 2005). They have glial-like functions in taste buds, expressing different
receptors such as GLAST or NTPDase2. The presence of GLAST indicates it is involved
in glutamate uptake and the NTPDase2 nucleosidase hydrolyzes extracellular ATP, a
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neurotransmitter in taste cells. Thereby, clearing excess neurotransmitter around the cells
(Bartel, Sullivan, Lavoie, Sévigny, & Finger, 2006; Finger et al., 2005; Lawton, Furness,
Lindemann, & Hackney, 2000). It also expresses the potassium channel, ROMK, involved
in K+ ion homeostasis in cells. Type I cells eliminate K+ ions from the interstitial spaces
of cells (Dvoryanchikov, Sinclair, Perea‐Martinez, Wang, & Chaudhari, 2009).
1.3.2 Type II taste cells
Type II cells are elongated taste sensory cells, that extend from the taste pore to the
base of the taste bud. They have a large nucleus and have transmembrane G protein coupled
receptors (GPCR) in the plasma membrane for transduction of sweet, bitter and umami
taste (Tomchik, Berg, Kim, Chaudhari, & Roper, 2007). These cells are characterized by
an abundance of mitochondria and vacuoles spread across the cytoplasm (Farbman, 1965).
It has been hypothesized that these cells play a role in the maintenance of taste cells.
Once GPCRs are activated by their specific ligands (taste stimuli), it transduces the
downstream signaling pathway by a specialized G-alpha subunit specific for a taste
stimulus (Nelson et al., 2001). This activates a second messenger pathway that leads to the
release of a neurotransmitter. Type II cells are characterized by the afferent nerves close to
the cell instead of forming pre-synaptic endings ( R. G Murray, 1969; Ruibiao, 2000). The
signal is transmitted to the nerve endings by the release of ATP functioning as a
neurotransmitter, induced by the voltage gated Na+ and K+ ion channels present within the
cell membranes. The ATP neurotransmitter release is through connexin or pannexin
hemichannels (Nelson et al., 2001) where it can activate either Type III cells or the adjacent
nerve fiber through P2X2/P2X3 receptors.
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1.3.3 Type III taste sensory cells
Type III cells are very similar to the Type II cells in their shape and electron density
but characterized by its abundant presence of numerous endoplasmic reticula. Type III cells
are characterized by pre-synaptic nerve endings that innervate the taste sensory cell
membrane. These cells are also characterized by the presence of ubiquitin carboxyl
terminal hydrolase PGP9.5, Serotonin 5-HT and neuron specific enolase, commonly found
in rats and mice. These cells are known to be found more centrally than peripherally within
the taste bud with a single microvillus at its apical end (Yee, Yang, Böttger, Finger, &
Kinnamon, 2001).
These cells are known to express proteins such as SNARE complexes, involved in
synaptic junctions with nerve terminals & Fujimoto, 1969; Ruibiao et al., 2000). Neuronallike genes expressed by these cells produce NCAM, enzymes to synthesize
neurotransmitters, an adhesion molecule over the cell surface, and voltage-gated Ca2+
channels for neurotransmitter release. These are presynaptic cells that express a range of
voltage-gated Na and K channels to induce action potentials. These cells are also known to
respond to signals generated by nearby cells (DeFazio et al., 2006; Gao et al., 2009; Medler,
Margolskee, & Kinnamon, 2003; Vandenbeuch & Kinnamon, 2009). The likely
neurotransmitter for these cells is serotonin.
1.3.4 Basal cells
Basal cells are often identified as Type IV cells (Barlow, 2015). These are immature,
post-mitotic cells, located at the base of the taste bud. Transit amplifying cells divide
symmetrically to give rise to the basal cells. These migrate into the taste bud under the
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influence of proper signaling mechanism within the taste bud to differentiate into mature
taste sensory cells, such as Type I, II or III.

1.4 TRANSDUCTION OF TASTE STIMULI
1.4.1 Salt taste transduction.
The primary salt taste transducer has been identified to be amiloride-sensitive
epithelial sodium channels (ENaCs) which are widely present in the Type I taste sensory
cells. These channels allow the influx of sodium ions into the taste sensory cells to
depolarize it. These ion channels are known to be inhibited by amiloride in micromolar
quantities. ENaC channels are composed of three homologous α-, β- and γ-ENaC subunits.
All three subunits of ENaC channels are found in all papillae present in the tongue but at
different degrees (Gilbertson, Damak, & Margolskee, 2000). In vitro preparation of rat
lingual epithelial cells, when exposed to sodium chloride, induces a slow inward current
which is reduced when amiloride is introduced (Heck, Mierson, & DeSimone, 1984).
Influx of Na+ ions induce a voltage-gated outward current.
Recent studies with Types II and III cells have also provided some indication that
they could certainly be involved in salt taste transduction. Calmodulin (CALHM1) a group
of hexamer channels present in the cell membrane of Type II cells involved in ATP release,
could be implicated in salt taste transduction. Experiments conducted using CALMH1
knockout animals showed smaller responses to NaCl stimuli in the chorda tympani nerve
of knockout animal than Wild Type animals (Tordoff et al., 2014).
Amiloride-insensitive salt responses were exhibited by Type III cells which
responded to the anions instead of cations to induce a transepithelial potential. Single cell
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calcium imaging showed responses to anions in these sour taste sensing cells
(Lewandowski, Sukumaran, Margolskee, & Bachmanov, 2016).
1.4.2 Transduction of Sweet, Bitter and Umami
Type II taste sensory cells are responsible for sweet, bitter and umami taste
transduction. These taste stimuli are detected by a heterogenous population of receptors
activating transmembrane GPCRs to induce the downstream signaling pathway for the taste
stimulus. The family of GPCRs involved in taste transduction in Type II cells comprises
of three distinct groups: mGluR, T1Rs, and T2Rs (Chandrashekar et al., 2000a; Jiang et
al., 2004; Simon, de Araujo, Gutierrez, & Nicolelis, 2006)
The T2R family of receptors are involved in bitter taste detection and transduction.
Different sets of genes encode T2R receptors in the taste cells (Chandrashekar et al.,
2000b). These range between 20-35 different genes among mammals. These taste receptors
have varying degrees of receptivity towards taste stimuli. Some of these receptors are either
narrowly or broadly tuned, which means some of the receptors identify and transduce a
specific set of ligands, whereas others identify a range of different ligands (Meyerhof et
al., 2010). In-situ hybridization has shown T2R mRNAs are co-expressed in the receptor
cells. Partially overlapping nature of taste receptors explains our ability to discriminate
between different bitter taste stimuli.
The T1R receptor family is comprised of three receptors that form heterodimeric
pairs. The heterodimeric form of T1R receptors, T1R2+T1R3, is responsible for the
detection of sugars and artificial sweeteners. Despite of lacking T1R3, some mice are still
able to detect sweet taste stimuli, indicating other, unidentified receptors are also involved
in detection of sweet substances (Damak et al., 2003). A2B adenosine receptors has been
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implicated in the enhancement of sweet taste reception. Prior research has shown the ATP
released from the cells were broken down to adenosine which evoked Ca2+ signaling in
cells to enhance the sweet taste in the presence of stimuli (Dando, Dvoryanchikov, Pereira,
Chaudhari, & Roper, 2012).
Previous research showed heterodimeric receptors T1R1+T1R3 are involved in
umami taste stimuli. Umami taste is characterized by L-glutamate and GMP/IMP
compounds. These compounds are indicators of protein in food. Further research using
ratiometric calcium imaging with Fura-2 of isolated taste sensory cells from C57BL/6J and
T1R3 knockout animals showed physiological responses when stimulated with Lglutamate, L-serine and IMP. These data suggest that these cells responded to a broad array
of amino acids and that there are additional receptors involved in umami taste detection.
Recent behavioral and calcium imaging experiments have shown that mGluR receptors
also respond to glutamate and other L-amino acids (Choudhuri, Delay, & Delay, 2015)
T1R family of receptors are categorized within the class III GPCRs, with Nterminal extracellular domains forming a Venus flytrap structure for ligand binding (Cui et
al., 2006; Max et al., 2001). T2Rs are categorized as a class I GPCR with transmembrane
binding sites (Floriano et al., 2006). Binding of the ligand to members of either family of
7 transmembrane GPCRs induces conformational changes that activates heterotrimeric Gproteins. The heterotrimeric G-proteins are composed of alpha, beta and gamma subunits.
Activation of the G-protein is characterized by the coupling of GTP to the alpha subunit
and the separation of the alpha subunit from the beta-gamma subunit (Spielman, 1998).
Furthermore, with the activation of the receptor, the βγ is released to induce the
downstream signaling pathway by interacting with a phospholipase C (PLCβ2). The
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phospholipase stimulates IP3 production to open the endoplasmic reticulum to release
Ca2+ ions into the cytosol. The released Ca2+ ions target both TRPM5 channels
responsible for Na+ ion influx and a gap junction hemichannel, responsible for ATP
neurotransmitter release (Simon et al., 2006)
1.4.3 Sour taste transduction
Sour taste is a result of acid concentrations within the vicinity of taste sensory cells
in the tongue. The concentration of H+ ions determines the sourness of the stimulus. Like
other tastes, sour taste also seems to be modulated by specialized receptors at the periphery.
Studies suggest the polycystic kidney disease-like ion channel (PKD2L1) may play a role
in sour detection. One of these studies used bioinformatics screening and in-situ
hybridization technique to identify the receptor’s involvement in sour taste transduction.
This study involved genetic ablation of taste cells with diphtheria toxin to induce loss of
specific taste receptors to see if there was a loss of sour taste. Ablated T1R resulted in the
loss of only sweet taste. Similarly, loss of PKD2L1 saw a loss of acid taste (Huang et al.,
2006). In-situ hybridization and double-labeled fluorescent immunohistochemistry was
conducted to investigate the co-expression of receptors specific for different tastes such as
T1R, T2R or TrpM5 with the candidate sour taste receptor, PKD2L1. The result showed
no co-expression of the mentioned receptors with PKD2L1.

1.5 TASTE BUD DEVELOPMENT AND RENEWAL
1.5.1 Brief timeline of taste bud formation
The development of taste buds has been investigated in mice beginning at an
embryonic stage until clear differentiation of the taste structure occurs after birth. At an
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embryonic stage day E11, a rudimentary structure of tongue forms, characterized mostly
by its epithelial bilayer. At embryonic stage E12.5 taste placode formation occurs, which
is basically the arrangement of undifferentiated columnar cells beneath the epithelial
bilayer, which eventually forms the differentiated taste cells. The placodes are surrounded
by sensory nerves. At E15.5-18.5 taste papillae morphogenesis begins with the formation
of the mushroom shaped structure, an apical localization of the immature taste buds and
sensory nerve innervation. About a week after birth, the mature taste bud appears in
fungiform and circumvallate papillary structures (Barlow, 2015; Kapsimali & Barlow,
2013).
1.5.2 Taste bud cell renewal
Taste cells have an average life span of about 10-14 days in rodents, suggesting it
gets continually renewed within a short span of time (Beidler & Smallman, 1965; Farbman,
1980). During any given day, about 10% of cells are lost due to natural attrition, 20-30%
of the cells are new and differentiating simultaneously, the remaining 60-70% of the cells
are functional taste cells (Barlow, 2015).
Studies using inducible lineage tracing techniques have identified cytokeratin, K5
and K14 markers, in the taste progenitor cells. These progenitor cells are responsible for
replacing the cells within the taste buds. These progenitor cells self-renew and divide to
give rise to the ovoid-shaped basal cells. The basal cells or Type IV cells reside within the
basal region of taste buds, migrating to the taste bud structure under proper signals from
within the bud. The basal cells express sonic hedgehog (Shh) signaling to regulate the cell
renewal process (Miura, Scott, Harada, & Barlow, 2014). Subsequently, the immature
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basal cells migrate into and mature within the taste bud structure to give rise to the different
types of taste cells.
1.5.3 Signaling mechanism for taste bud development and renewal
1.5.3.1 Hedgehog Signaling. Shh is a factor generally expressed by the taste bud
basal cells. Shh induces transcription of its target genes Gli1 and Ptch1 in progenitor cells
located outside the taste buds and are involved in regulating cell replacement in taste
buds. Shh’s role as a cell regulating factor was revealed by developmental experiments
where inducible genetic model expression was used. This study also showed that excess
Shh induces an overexpression of ectopic taste buds on the anterior filiform section of
the tongue (Castillo et al., 2014). Drug-induced disruptions in the Shh signaling pathway
have resulted in taste-related complaints from patients undergoing chemotherapy. Some
of these drugs directly impact factors such as Smoothened (Smo) within the Hedgehog
signaling pathway, thereby disrupting the normal cell differentiation cycle resulting in a
reduced number of taste cells over a period and a loss of taste function. But this loss in
taste is reversible and comes back with the removal of the drug (Kumari et al., 2015).
1.5.3.2 Wnt/β-catenin Signaling. Embryonic taste bud or taste placode
development is induced by the Wnt/β-catenin pathway within the taste bud. The Wnt
pathway remains active in the adult mature taste cells, specifically the BATGAL reporter
mice expressing β-galactosidase in the presence of β-catenin. Its presence is detected all
the way from the progenitor cells until the mature taste sensory cells, implicating its
importance in cell lineage within the taste system (Gaillard & Barlow, 2011).
This signaling pathway also plays an important role in the mature taste bud. For
example, BATGAL reporter mice express beta-galactosidase in progenitor cells as well
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as in taste sensory cells in the presence of b-catenin, suggesting this pathway is
responsible in taste cell renewal to give rise to the mature taste sensory cells. The role of
β-catenin was tested by overexpressing β-catenin in K5+ basal keratinocytes and
observing differentiation of K5+ cells into mature taste sensory cells, predominantly
Type I cells (Barlow, 2015).

1.6 GUSTATORY AFFERENT TASTE PATHWAY
Initially information about taste begins with taste receptors. This information is
transmitted by the cranial nerves located close to the anterior and posterior end of the
tongue to the brain stem. Each taste bud in humans is innervated by 4-14 sensory neurons
which penetrate the basal lamina to enter the taste buds and are extensions of cranial nerves.
The anterior 2/3rd of the tongue is penetrated by cranial nerve VII, the facial nerve, and the
posterior end of the tongue is innervated by the glossopharyngeal nerve, cranial nerve IX.
Finally, the third set of cranial nerves is known as the vagus nerve (cranial nerve X)
surrounding the throat and its adjacent area (Hamilton & Norgren, 1984). The cell bodies
of the neurons are present in geniculate, petrosal and nodose ganglia of cranial nerves VII,
IX, and X, respectively. Gustatory nerve fibers co-mingle as a plexus in the oral cavity
under the taste epithelium (Krimm & Hill 1998; Vandenbeuch & Kinnamon, 2009). It is
almost impossible to determine the nerve fibers within a taste bud responsible for specific
taste information due to the unavailability of clear marker of those neurons to distinguish
between different types of neurons (Farbman, 1965). Immunostaining and retrograde
tracing have helped identify the taste pathway in rats from the peripheral region to the
sensory cortex. Neurons link each structure of the pathway. It begins at the nodose ganglion
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(periphery) which sends axons to the solitary nucleus in the medulla. Projection cells in
this nucleus send axons all the way up to parabrachial nucleus of the pons. These neurons
project their axons to the ventral posterior medial nucleus in the thalamus which
subsequently send their axons to the taste sensory cortex of the rodent brain (Hamilton &
Norgren, 1984).

1.7 TASTE CODING
Taste coding is referred to as the process by which the peripheral signal detected
by the taste sensory cells is converted to neural signals for the transmission to the brain
cortical region. There currently are two theories of taste information coding. Labelled line
model states that a basic taste is transduced by only one type of taste receptor and
transmitted by one type of nerve fiber associated with that taste. The across neuron pattern
model states that a taste can be transduced by different receptors and the information is
transmitted to the brain by more than one type of nerve fiber (Erickson, 1982; Hellekant,
Ninomiya, & Danilova, 1998) and taste identification is determined by the collective neural
codes of all fibers conveying the information.
Evidence towards labeled line coding can be found in T2R receptor isolation, Gprotein coupled receptors, which are expressed in subsets of taste sensory cells found in
the tongue and palate. T2Rs are responsible for detecting bitter taste stimuli exclusively,
even though both humans and mice cannot differentiate among different forms of bitter
compounds. The study used heterologous expression system to identify the receptors’
function in detecting bitter stimulus. Both the human and the mouse T2R receptors
responded to denatonium and cycloheximide respectively (Adler et al., 2000;
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Chandrashekar et al., 2000). T2Rs discriminating different types of bitter taste is an
indication of broader coding in cells. On the contrary, these cells are exclusively expressed
in α-gustducin expressing cells, also known as the Type II cells is an indication of labeled
line coding.
Labeled line coding in taste could also be seen in sweet taste transduction, which is
detected by T1R family of receptors. Sweet is detected and transduced by heterodimeric
combination of T1R2 and T1R3 receptors. It can detect a wide range of sweet tasting
compounds such as sucrose, saccharin or dulcin (Nelson et al., 2001). Even though its
exclusive detection of sweet taste suggests a labeled line coding towards a specific taste
response, its inability to differentiate among different sweet tasting compounds suggest an
across fiber pattern coding within the periphery (Ahmed & Hombal, 1984).
With regards to the taste coding within the cortical regions of the brain some studies
suggest the presence of specific regions or a group of neurons which exclusively respond
to specific taste stimuli. For example, a study conducted on mice using in-vivo two photon
calcium imaging suggests different topographic segregation within the cortical regions
(Zhang et al., 2003).
Across fiber pattern coding in the cortical region could also be understood and best
represented by the relative levels of activity in the afferent neuron population carrying
information to the cortical region. A study involving whole mouth stimulation with various
compounds have shown the presence of a groups of neurons responding to a stimulus better
than others, even though responding to other stimuli as well. Utilization of bitter
compounds have detected the presence of bitter best neurons responding mostly to a variety
of bitter stimuli (Geran & Travers, 2006).
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All the above studies suggest a combination of different types of coding processes
within the taste sensory system. These processes begin at the periphery and end up within
the cortical region of the brain to process the taste information.

1.8 CHEMOTHERAPY DRUGS
Cancer is a disease affecting millions worldwide. The predominant mode of
treatment is either chemotherapy or radiation or their combination. Chemotherapy involves
the use of toxic drugs to disrupt the cell replication cycle by inducing cell death of
proliferating cancer cells. Chemotherapy drugs interact with rapidly dividing cells and are
non-specific in action to induce cell death. Use of these drugs therefore results in cell death
at various regions of the body where normal cells are proliferating, hence its side effects.
Chemotherapy drugs are classified into different classes, based on its mode of action. They
are the following: alkylating agents, antimetabolites and topoisomerase inhibitors.
1.8.1 Alkylating Agents
These drugs are among the first developed drugs used for cancer treatment. They
were developed during the World War I era (Corrie, 2008). These drugs can alkylate DNA
or RNA by transferring an alkyl group to the strand via covalent bonds. Subsequent
replication cycle results in strand breaks (Lind, 2008). These drugs non-selectively target
proliferating tumor and normal cells to induce cell death (Corrie, 2008). Due to their nonselective nature, these drugs have a dose-dependent toxic effect over the cells. A few
different subtypes of this type of drugs are nitrosourea, nitrogen mustards, tetra-zines,
cisplatin and cyclophosphamide (Giorgi-Renault et al., 1988).
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1.8.2 Antimetabolites
Anti-metabolites are a group of drugs or molecules that prevent the synthesis of
DNA or RNA. Instead of the usual nucleotides synthesizing into long chains of DNA, it is
replaced by chemical groups similar in structure to the nucleotides or nucleosides. They
also induce its effect by inhibiting the enzymes involved in the normal synthesis of DNA
(Parker, 2009). For example, anti-metabolites such as methotrexate inhibits dihydrofolate
reductase (DHFR). This enzyme is involved in purine production, essential for DNA
synthesis (Hillcoat, Swett, & Bertino, 1967).
1.8.3 Topoisomerase inhibitors
Topoisomerase inhibitors are chemical compounds affecting the normal activity of
topoisomerase I and II. The torsion created due to the processes of replication and
transcription cause an overwound DNA double strand, thus not allowing DNA polymerase
to traverse down the double stranded DNA. Hence, topoisomerases are enzymes
responsible for creating temporary nicks within the DNA double or single strand to release
the stress induced by these processes. The topoisomerases are classified into sub-types I
and II (Champoux, 2001). Topoisomerase I inhibitors are involved in trapping the
intermediate complex of TOPI cleavage complex, rendering it useless. Camptothecinderived compounds belong to this category (Pommier, 2006).
1.8.4 Cyclophosphamide
Cyclophosphamide is one of the earliest and most effective anti-neoplastic drugs
formulated and is still in use. Cyclophosphamide is an anti-neoplastic drug belonging to
the class called alkylating agents and has immunosuppressive properties. It is used in the
treatment of different forms of cancer including leukemia, lymphoma and breast cancer.
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This drug kills rapidly proliferating cells and resting lymphoid cells. It is also regularly
used post tissue transplantation and diseases which could be a result of inflammation
(Gershwin et al, 1974; Orjuela et al., 2003). Alopecia, nausea, myelosuppression or
hemorrhagic cystitis are just a few of the toxic effects (Ahmed & Hombal, 1984). Even
though the drug is predominantly used for the treatment of cancer, it can also induce cancer
in patients. Cyclophosphamide is also used in the treatment of neuroblastoma and
carcinomas of different organ system such as lung, breast and gastrointestinal systems
(Gershwin et al., 1974)
1.8.4.1 Metabolism. Metabolism of this compound occurs within the liver, induced
by the cytochrome P450 isoforms, CYP2A6, 2B6, 3A4, 3A5, 2C9, 2C18, and 2C19. The
two metabolites formed are phosphoramide mustard and acrolein. Phosphoramide mustard
is the compound responsible for most of its antitumor or the chemotherapeutic effects.
Acrolein has been implicated in a wide range of diseases including multiple sclerosis,
cardiovascular diseases among others (Ramu, et al. 1995; Moghe et al., 2015). In cells it
can cause mitochondrial damage or oxidative stress (Moghe et al., 2015). Metabolic
pathway for the drug begins with activation within the hepatic cells. The cytochrome P450
enzyme
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hydroxycylophosphamide and aldophosphamide which exists in its tautomeric form. It is
then further oxidized to carboxyphosphamide. The aldophosphamide diffuses into the cells
to metabolize into the active compound phosphoramide-mustard and acrolein (McDonald
et al., 2003).
1.8.4.2 Mechanism of Action. The active metabolites from the drug, phosphoramide
mustard and to some extent acrolein, are known to be involved in anti-cancer activity.
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Phosphoramide mustard targets the N7 guanine ring of the DNA strands cross-linking the
DNA in proliferating cells to disrupt the cell cycle and, thus, prevents replication of cells.
Even though phosphoramide mustard is known to cause off target damage to normal cells,
the drug still exhibits quite a lot of specificity as the metabolite is hydrophilic and studies
show the tumor cell walls to be hydrophilic (Brock & Hohorst, 1967; Fleming, 1997).
1.8.5 Effect of chemotherapy on taste
Chemotherapy has a variety of side effects which includes the loss of immunity to
infections and the loss of sensitivity to taste and smell stimulation. Disruptions in taste and
smell can have a significant effect on the overall health and quality of the individual, both
psychologically and physically. The inability to taste food can result in a reduced intake of
nutritious food, thwarting the recovery of the patient and thus leading to a poor
psychological health (Comeau et al., 2001). Studies suggest that after chemotherapy
treatment, at least 40% patients are malnourished. Malnourishment results in a significant
decrease in the response to therapy (Comeau et al., 2001). Chemotherapy drugs that are
generally associated with taste-related dysfunctions are cisplatin, carboplatin or
cyclophosphamide to name just a few. Several studies with patients undergoing
chemotherapy have been conducted to identify the effect of these drugs on taste. One study
involving a small group of patients helped document the kind of taste changes that occur
with chemotherapy. Participants described tastes as either metallic, stale or musty.
Different patients described different taste dysfunctions. Some could detect sweet food and
others would dislike it or could not detect sweet at all. Similarly, some patients would have
a distorted sense of taste and would, for example, describe the taste of coffee as unusually
burnt (Bernhardson, Tishelman, & Rutqvist, 2007). Another study was conducted on a total
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of 518 patients, of which at least 134 patients developed taste-related changes. Some
patients had an immediate effect of drug treatment on their taste whereas others seem to
have an effect 10 weeks post first treatment. Most patients reported dysfunction in sweet
and salty taste sensation (Bernhardson, Tishelman, & Rutqvist, 2008).
Based on these patient accounts of taste-related changes, behavioral, cellular and
molecular studies have worked extensively using a mouse model to identify the underlying
cause of these changes. One study examining the effects of cyclophosphamide on umami
taste, found a two-phased drop in taste sensitivity after injection of 75mg/kg of the drug.
The first drop was associated with a sharp drop in the number of fungiform papillae which
did not show improvement in number until 12 days post-injection. A similar decrease in
the number of taste buds for circumvallate papillae began about 8 days post injection
(Mukherjee & Delay, 2011). Morphological studies like these, demonstrate the decline in
taste papillae has a significant role for drug-related changes in taste. A more immediate
effect of the drug on taste sensory cells was observed in a study using cell death assays to
examine the effects of cyclophosphamide. TUNEL assays on fungiform and circumvallate
taste buds show a peak in cell death at around 6-8 hours post injection. Caspase-3 assay of
apoptosis showed that a second wave of cell death began 12 hours post injection, peaked
at 18-24 hours and returned to control levels within 48 hours. This suggests that the drug
acts quite quickly resulting in taste cell loss from within the taste papillae (Mukherjee et
al., 2017).
1.9 CYTOPROTECTIVE AGENTS
Chemotherapy or radiotherapy commonly used to treat cancer, have their own side
effects and toxicities, which could be acute, for a short phase or it could be cumulative,
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leading to severe consequences, sometimes death (Rose, 1996). Often to mitigate these
effects, the dosage for the drugs or radiation is modulated within its therapeutic index,
which is the ratio of the therapeutic effect of the drug to the toxicity caused by it. There are
no fixed and effective treatment procedure that could be involved to prevent toxicity related
to these drugs but use of cytoprotective agents such as amifostine could help reduce its
harmful effect. One very important aspect of these protective agents is their ability to
preferentially treat normal cells from cancerous or damaged cells. Amifostine has been
extensively studied and its efficacy in preventing damage induced by chemotherapeutic
has been established (Mukherjee et al., 2013)
1.9.1 Amifostine
Amifostine is a thiol-based sulfhydryl drug developed by Walter Reed Army
institute of Research. About 4000 sulfhydryl compounds were tested for their
cytoprotective effects, out of which only one compound, WR-2721 also known as
amifostine, was chosen (Grdina, Kataoka, & Murley, 2000). Amifostine is one of the few
drugs providing protection to normal cells from chemotherapy-induced damage (Yuhas,
1980). This drug has been approved by FDA for both chemotherapy as well as radiotherapy
and it has been extensively used to prevent xerostomia in patients undergoing head and
neck radiotherapy ( Rose, 1996).
1.9.2 Pharmacology of amifostine
Amifostine is a hydrophilic compound and, therefore, does not generally cross cell
membranes. It is a pro-drug, which means that it remains inactive in its native state and is
activated only after it dephosphorylates to its active metabolite WR1065 either due to the
hydrolysis catalyzed by alkaline phosphatase in normal cells or due to spontaneous
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hydrolysis within cells. This compound’s therapeutic property is determined by greater
uptake of this compound in normal tissues than in tumor tissues (Yuhas, 1980; Utley et al.,
1984). This differential uptake of the drug can be further explained by the fact that an acidic
environment within tumor cells prevents the activity of alkaline phosphatase within cells
as well as the abnormal vasculature of tumor tissues (Calabro-Jones, Fahey, Smoluk, &
Ward, 1985). The active metabolite of the drug is eliminated having a half-life of about 30
minutes in lung and skin, whereas it is eliminated more slowly in salivary glands which
requires about 3 hours (Utley et al., 1984).
1.9.3 Mechanism of Action
The mode of action of amifostine begins with the metabolism of the drug to its
individual active metabolites WR1065 and WR33278. It is believed that both compounds
are involved in scavenging free radicals within the cells in competition with oxygen. At
an intermediate level of oxygen, the protection is maximum. High oxygen levels result in
the loss of protection whereas at low cellular oxygen level, the metabolites do not provide
any protection because the cells are self-protected. In addition, the metabolite WR33278
is structurally like naturally occurring polyamines which are involved in DNA
stabilization and repair, and therefore has an antimutagenic effect in cells (Perrin,
Kataoka, Grdina, & Basic, 1992).
1.9.4 Toxicity and administration of the drug
Amifostine does not appear to have a major toxic effect but it does have some dosedependent effects that require attention. A higher dose than what should be administered,
could potentially result in hypotension. When used with radiotherapy, a patient requires
close monitoring at lower doses due to the possibility of hypotensive conditions.
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Antiemetics are generally administered along with the therapy to prevent nausea and
vomiting, which is a possibility at higher doses (Andreassen, Grau, & Lindegaard, 2003).
Phase 2 trials of the drug suggested an acceptable dose of 740 to 910 mg/m2 as a
cytoprotective agent. Furthermore, FDA suggested a dose of 910 mg/m2 pre-injection in
patients undergoing cisplatin-based chemotherapy to prevent nephrotoxicity in patients
whereas a recommended dose of 200 mg/m2 is to prevent radiation-induced xerostomia.
Most preferable mode of administration has been via a subcutaneous injection. Both phase
1 and phase 2 trials using subcutaneous injection, have suggested very promising results.
Benefits have been lower incidents of hypotension, bladder toxicity and mucosal reactions
in patients (Andreassen et al., 2003;Koukourakis et al., 2000).

1.10 INFLAMMATION
Inflammation is an immune response to drug or infection induced injury to cells
and tissues. Inflammation is characterized by redness, swelling or vascular permeability
within tissues resulting in the accumulation of immune cells and small molecule cytokines,
involved in a cellular or humoral immune response to pathogens at the site of injury. There
are different soluble factors involved in immune responses which can be categorized into
groups such as: 1) lipid metabolites, platelet activating factor (PAF) or prostaglandins, 2)
soluble proteases or substrates releasing multiple pro-inflammatory peptides, 3)
compounds such as nitric oxide, which is a vasodilator, and 4) small protein molecules
released by immune cells called cytokines which could have both a negative or a positive
effect over cells and tissues. For our study, the focus will be on cytokines as an
inflammatory mediator (Feghali & Wright, 1997). For the next few paragraphs my
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discussion will be on cytokines commonly found within the gustatory papillae. Some of
the cytokines involved in acute inflammation are the interleukins IL-1, IL-6, IL-8 or Tumor
Necrosis Factor-α (TNFα). Inflammation is a component due to which an immune response
within the cellular system is initiated, possibly leading to a rapid cell death. Thus, this
section discusses the introduces inflammation and its components such as the cytokines.
1.10.1 Interleukin-1
IL-1 α and β are encoded by different genes located in the chromosome 2 and are
of the size 22-31kDa and 17.5kDa. These molecules are secreted by different types of
immune cells such as phagocytes, fibroblasts or lymphocytes. These molecules are known
to trigger inflammation in the form of fever by inducing the production of prostaglandins
E2 (PGE2) by the vascular endothelium and the release of histamines from mast cells.
Histamines are known to cause vasodilation within blood vessels. The pro-inflammatory
effect of the cytokine IL-1 can be inhibited by IL-1 receptor antagonist such as IL-1ra, a
naturally occurring inhibitor having physiological functions in the humans (Feghali &
Wright, 1997; Warren, 1990; Dinarello et al., 1991).
1.10.2 Tumor Necrosis Factor
Tumor necrosis factor is found both as an α and β form. They are 17kDa and 25kDa
in weight. TNF-α exists as a trimer and is produced by macrophages, fibroblasts, mast cells
and NK cells. This is a pro-inflammatory cytokine which shares inflammatory properties
with IL-1 such as the production of prostaglandins. TNF-α is also known to induce the
production of other cytokines such as IL-6 in several other cell types. During infection
from bacteria, induced by lipopolysaccharides, macrophages release TNF-α and its effects
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are both autocrine, paracrine and endocrine. TNF is known to cause major metabolic
disruptions and well as associated with some cancers (Idriss & Naismith, 2000).
1.10.3 Receptors for Cytokines
Cytokines elicit their responses in cells by binding to cell surface receptors to
induce downstream signaling pathways. For example, the IL-6R comprises of two subunits,
an 80kDa ligand binding molecule and another 130kDa signal transducing subunit. Tumor
necrosis factor receptors are 55 and 75kDa in size that binds both TNF-α and β (Idriss et
al., 2000). Both receptors share some identity in its extracellular domain. Even though
cytokines bind to specific receptors, some share common signaling pathways inducing a
cellular response. For example, IL-6 and IL-11 even after having different receptors share
a common downstream signaling pathways (Feghali & Wright, 1997).
1.10.4 Inflammation and its implication on taste disorders
Extensive research on inflammation within the taste sensory organ has shown the
presence of inflammatory cytokines and signaling mechanism in the taste sensory cells.
Findings reveal the presence of TLR receptors and interferon signaling pathways in
different types of taste sensory cells. As earlier mentioned, the inflammatory pathways and
cytokines are essential for maintaining the integrity of taste buds but could be severely
deleterious if expressed at a higher level (Wang, Zhou, Brand, & Huang, 2009).
Most of the studies on inflammation in the taste sensory system have been to
investigate an infection induced inflammatory model either by using Lipopolysaccharide
or RNA polycytidylic acid. Wang’s studies have corroborated, for example, the presence
of cytokines such as IL-10 an anti-inflammatory cytokine responsible in maintaining the
integrity of the taste buds, as well as TNF-α, a pro-inflammatory cytokine important in cell
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growth and survival in specific subsets of taste sensory cells, primarily in the Type II cells.
It must be noted the presence of both pro- and anti-inflammatory cytokines suggest a
physiological phenomenon to compensate for the effect of either of the cytokines (Feng et
al., 2014; Feng, Zhao, Chai, Huang, & Wang, 2012).
Similar work to identify an Interferon signaling pathway and its receptors were
investigated by Wang’s group and found the receptor IFNGR1 co-expressed with neuronal
cell adhesion molecule and gustducin expressing taste sensory cells. The presence of these
receptors was corroborated by the phosphorylation of downstream STAT1 transcription
activator. Administration of IFN has been shown to induce cellular death in taste buds
(Wang, Zhou, Brand, & Huang, 2007).

1.11 CELLULAR DEATH
Understanding cellular death may help us understand more about how
chemotherapy drugs such as cyclophosphamide affects the taste system. Cell death is an
essential homeostatic mechanism in multicellular organisms which generally maintains the
overall architecture by removing damaged cells that could be detrimental to the well-being
of the organism. There exist three distinct modes of cell death: apoptosis, autophagic cell
death and necrosis. Apoptosis is a controlled cell death process whereby the cells dismantle
without causing any damage to the nearby tissues. Autophagy is more of a survival process
where membrane engulfment along with catabolic degradation of cytoplasmic materials
occur as a response of metabolic stress within cells. Necrosis is the form of cell death
resulting from any cellular injury and toxin. It is characterized by loss of plasma membrane
integrity and swelling. All the above-mentioned modes of cell death occur during different
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phases of inflammation which could be the result of the cytokines inducing the immune
cells to cause cell death. Understanding the nature of cell death following tissue damage
can be quite important (Green & Llambi, 2015).
1.11.1 Apoptosis
Apoptosis, also known as programmed cell death, is characterized by cell
shrinkage, blebbing, and condensation of chromatin ultimately leading to cell death via
phagocytosis by macrophages. Apoptosis is a well-regulated process which, when it fails,
causes serious pathological conditions. This is a caspase-mediated cell death. An initial
understanding of apoptosis was investigated in Caenorhabditis elegans which precisely
form 1090 cells of which 31 of them die post development. There are two modes of
apoptosis which is mediated by different but converging pathways: a mitochondrialmediated pathway (also known as the intrinsic pathway) and a death receptor pathway
(Kerr, Wyllie, & Currie, 1972). The death receptor pathway is initiated by a ligand binding
to membrane surface receptors such as CD95, TRAIL-R or TNFR1 that activates a
downstream signaling pathway to recruit caspases. The membrane receptors such as
TRAIL oligomerize after ligand binding to recruit Fas associated death domain and
caspase-8 forming a complex called DISC. At this point effector caspases such as caspase
3, 7 and 9 are activated downstream of the complex. In contrast, the mitochondrial pathway
is initiated by the loss of membrane integrity resulting in the release of cytochrome c which
binds to Apaf-1 and procaspase-9 to form the apoptosome complex. The intrinsic or the
mitochondrial pathway is initiated due to either DNA damage or cellular stress. Both
pathways converge onto caspase-3 and other proteases to move the process of cell death
ahead. The final step of the entire process involves the recognition of markers such as
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phosphatidylserine to finally phagocytose the cell. Pro-survival signals regulate proapoptotic mechanism within cells. Bcl-2, IAP or NF-kB are just some of the protein
molecules involved in the process (Green & Llambi, 2015; Yu et al., 2005; Zou, Henzel,
Liu, Lutschg, & Wang, 1997)
1.11.2 Necrosis
Necrosis is an unregulated process and often can lead to an inflammatory condition
in and around tissues. It is characterized by vacuolation of the cytoplasm and disintegration
of plasma membrane. It is an energy independent process and the condition occurs when
the metabolic processes within the cells break down. A very well-known example of when
this process begins is during ischemia. Lack of oxygen, glucose and other factors could
result in necrotic cell death in non-proliferating cells (Yuan & Kroemer, 2010)
Evidence suggests necrosis can be induced by microbial infection, reactive oxygen
species (ROS), toxins, tissue injury and can be a component of normal physiological
processes. Often when the small intestinal tissue is renewed both apoptosis and necrosis
has been involved in cell death (Günther, Neumann, Neurath, & Becker, 2013). Studies to
determine whether necrosis could be a possible method of cell death in tissue development,
found that genetic deletion of caspase-3 and caspase-9 do not affect the neuronal loss in
spinal cord. DNA alkylating agents can induce necrotic cell death initiated by PARP, in
proliferating cells. The inflammatory component of necrotic cell death in tumors could
induce an immune response which could result in an efficient tumor cell loss (Zong,
Ditsworth, Bauer, Wang, & Thompson, 2004)
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1.11.3 Autophagy
Autophagy is an evolutionarily conserved lysosome mediated pathway which has
several important functions. It is important during remodeling and differentiation of tissues,
produces amino acids during limited nutrient availability and gets rid of damaged
organelles within cells. Autophagy is a stimulated process which means it is activated
during oxidative stress, or the accumulation of misfolded proteins, hormonal signaling, and
irradiation (Kroemer & Levine, 2008; Shen, Kepp, & Kroemer, 2012).
1.11.4 Summary on cell death
One of the common mechanisms by which chemotherapy drugs induce cellular
damage is apoptosis. Cell death or apoptosis is induced via signaling pathways within the
cells which are activated by Death Receptors, such as the TNF family receptors, resulting
in caspase activation and recruitment. These processes finally converge at a single event,
mitochondrial membrane permeabilization, which leads to cell death. Some of the
cytotoxic agents directly affect the mitochondria by acting upon the bcl-2 family proteins
or adenine translocase within these cells (Debatin, Poncet, & Kroemer, 2002).

1.12 RESEARCH QUESTION AND HYPOTHESIS
Chemotherapy-induced taste sensory loss is commonly documented in patients
undergoing chemotherapy, resulting mainly in malnutrition. Some of the behavioral and
cellular experiments in our lab suggested the loss of taste buds over a course of time has
been responsible for an augmentation of taste detection threshold for common tastes.
Cyclophosphamide is an alkylating agent which causes toxicity by disrupting the cell
replication cycle. Studies in our lab suggest that cyclophosphamide has a toxic effect within
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hours of administration and a second wave of toxic effects detectable within 18-24 hours,
corroborated by TUNEL and caspase-3 assays (Mukherjee et al., 2017) These findings
suggest that cyclophosphamide may cause an inflammatory response in the peripheral taste
system. Previously, studies have suggested lipo-polysaccharide, an outer layer of the
bacterial cell wall, mimics an infection that induces an inflammatory response in taste buds
and expresses pro-inflammatory cytokines in taste buds (Cohn, Kim, Huang, Brand, &
Wang, 2010; Wang et al., 2007) Our study explores the general hypothesis that a
chemotherapy drug induces an inflammation which could be a result of the insult that
chemotherapy-led toxicity imposes on the tissues.
More specifically, our investigation involves detection of Tumor Necrosis Factorα (TNFα), a pro-inflammatory cytokine expressed in the taste buds present in both
fungiform and circumvallate papillae.
My thesis is testing two hypotheses: 1) cyclophosphamide induces inflammation
in taste sensory system, specifically detecting the expression of TNFα in either Type II or
Type III cells within the taste buds, and 2) amifostine can protect the taste system from
cyclophosphamide-induced inflammation by reducing the levels of TNFα at least 24-hour
post CYP injection.
Our investigation involves Immunohistochemical labeling to detect TNF-α
along with the respective taste cell marker within the taste bud to identify the taste cells
over a period of 72 hours post-cyclophosphamide injection. A second component of this
experiment involves pre-injection of amifostine and then cyclophosphamide followed by
perfusion at 24-hour post injection and immunohistochemical labeling to determine the
reduction in the overall TNFα levels in taste sensory cells.
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CHAPTER 2: EXPRESSION OF PRO-INFLAMMATORY
CYTOKINE DURING CHEMOTHERAPY IN TASTE BUDS AND
AMIFOSTINE AS A CYTOPROTECTIVE AGENT
2.1 Introduction
The gustatory system is an important sensory system involved in distinguishing
nutritious from poisonous substances. It also is involved in preparing the gut for the
cephalic phase by secreting necessary enzymes and juices for the digestion of food. Any
disturbance in the taste sensory system can be deleterious for the overall health and wellbeing of humans. Disturbance in taste could be a result of infection, drug-induced injuries,
radiation, or other forms of insult (Chaudhari & Roper, 2010).
All these causes can have severe effects on gustation which can result in
avoidance of food and potentially long-term malnutrition. Chemotherapy is a major cause
of taste-related dysfunction in patients undergoing treatment (Comeau et al., 2001; Hong
et al., 2009). Taste dysfunctions generally are side-effects of treating cancer in patients by
targeting proliferating cells in different phases of replication cycles. However, these drugs
are often known to be non-specific and do not differentiate between healthy and cancercausing cells, thereby damaging healthy cells such as taste sensory cells (TSCs) along with
the cancer-causing ones (Mukherjee et al., 2017).
Chemotherapy drugs can elevate taste detection thresholds for basic tastes. Of 518
patients in one study who received chemotherapy at different centers, 134 complained of
taste sensory changes after a few weeks of treatment (Bernhardson et al., 2007;
Bernhardson et al., 2008). Chemotherapy patients also exhibited taste sensitivity deficits
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when tested with electrogustometric analysis. Electrogustometric analysis reliably tests the
functional integrity of nerves, taste sensory cells, and the brain centers for proper
functioning and taste detection (Berteretche et al., 2004). In addition, qualitative and
quantitative assessment of taste in patients undergoing chemotherapy, were done using
filter paper strips impregnated with basic taste substances. These patients also showed a
transient loss of taste compared to healthy controls. This study also reported the effect of
chemotherapy was more distinct on salt taste sensation than other basic tastes (Steinbach
et al., 2009).
There appear to be various reasons for a loss in taste sensitivity. For example,
cyclophosphamide (CYP), a well-established chemotherapy drug, raises taste thresholds
because it can kill TSCs, damage or alter taste bud structure, and disrupt cell proliferation
that is involved in replacing TSCs when they die (Mukherjee et al., 2017). Other secondary
effects of chemotherapy or radiotherapy include reduced saliva output due to damage to
the von-Ebner gland. Xerostomia can change taste thresholds due to lower production in
saliva which is important in making the nutrient available to the taste bud apical ends (Mese
et al., 2007; Mukherjee & Delay, 2011).
Research using behavioral assays with umami stimuli, found a biphasic pattern in
taste dysfunction after a single dose of CYP. Detection of umami taste showed a decline in
sensitivity during the first four days post injection and again beginning about eight days
post injection. Cellular assays confirmed a decline in mean fungiform papillae, both with
and without pores, 2-4 days post injection which did not recover for 12-16 days. In contrast,
circumvallate taste buds began showing a decline by 7-8 day and began to recover 12 days
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post injection (Mukherjee et al., 2013). A decline in the number of taste buds suggests a
direct cellular effect of the chemotherapy drug.
TSCs are epithelial cells, present in onion shaped taste buds, and are responsible
for taste detection and transduction downstream. TSCs are elongated cells spanning from
the apical pore to the basal end of the taste bud structure. There are about 50-100 TSCs
within the taste buds, and they can be of different types such as Type I, II, III and IV
(Farbman, 1965; Finger, 2005). Type I cells are mature columnar shaped, generate
protruding structures around other cell types, and act as a glial-like cell by expressing
GLAST and EctoATPase for neurotransmitter clearance. Type II cells are large, having a
round nucleus and expressing G protein-coupled receptors and downstream signaling
machinery for sweet, bitter or umami taste transduction. Type III cells are slender in
structure, characterized by synaptic contacts and the expression of synaptic membrane
protein, SNARE complexes (DeFazio et al., 2006). These cells have a short life span
ranging between 8 to 24 days with different cell types having differing life spans (Finger,
2005).
TUNEL and caspase-3 assays show CYP has a toxic effect on TSCs, causing cells
to die at a very early stage post injection. TUNEL assays, which detect fragmented DNA,
showed a peak response at 6-8 hours post-injection, whereas caspase-3 assays of apoptosis
revealed a peak signal 18-24 hours post injection. Results from these assays suggest an
early drug-related necrosis, followed by apoptosis in TSCs (Mukherjee et al., 2017).
Similar data were reported for TUNEL and caspase-3 in bladder inflammation after CYP
injection in rats (Jezernik, Romih, Mannherz, & Koprivec, 2003). CYP injections in rats
have also resulted in a significant expression of cytokine mRNA in the bladder tissue
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indicating an inflammatory response within the bladder (Jezernik et al., 2003; Malley &
Vizzard, 2002).
Inflammation is an immune response to either infection, tissue damage or toxicity
related to drugs and involves the expression of cytokines as an immune modulating factor
(Vakkila & Lotze, 2004). Inflammation within sensory cells within taste buds have been
shown to cause taste related disorders (Wang et al., 2009). Inflammation due to the
expression of cytokines in taste buds could be involved in cellular death as demonstrated
earlier in the activation of interferon signaling pathways. Administration of IFN-α
and IFN-γ had significantly increased programmed cell death of taste cells (Wang et al.,
2007).
Previous studies using lipopolysaccharide (LPS), a component of bacterial cell
wall component which mimics infection model, have found expression of proinflammatory cytokines within the taste sensory cells. Six hours after injections of LPS,
TNF-α (proinflammatory cytokine), IFN-γ and IL-6 (both anti-inflammatory) were found
localized within subsets of taste sensory cells. Induced by lipopolysaccharide injection,
TNF-α was found in the taste buds, co-localized and highly expressed in sweet and
umami sensing TSCs (Feng et al., 2012). TNF-α is a trimeric protein molecule known to
be released by immune cells such as monocytes, macrophages and activated by T
lymphocytes. TNF-α induces its effect by binding the trimeric protein to two types of
receptors, TNFR1 or TNFR2. TNF-α is known to have various purposes within the cells
such as activating signaling pathways or inducing immune response and inflammation. It
does have some protective effect, but with over-expression it could be deleterious to an
extent that results in cell death. Also, its name comes from its ability to cause necrotic
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cell death as documented in some tumor cells (Idriss et al.,2000). Prior work suggests it
is released constitutively in cells even during normal physiological conditions, perhaps
having broader functions in protecting cells (Feng et al., 2012).
In the present study, we looked at TNF-α in both fungiform and circumvallate
papillae after CYP administration to determine if it was co-localized in specific taste
sensory cells. TNF-α is a pro-inflammatory cytokine produced by immune cells such as
macrophages, lymphocytes and monocytes inducing an inflammatory reaction during any
abnormalities within the cells. It is also important in regulating multiple physiological
processes such as differentiation, proliferation and cell survival. Any dysregulation in its
normal cellular expression could affect multiple physiological processes and thus we
decided to investigate its expression in its role as an inflammatory marker causing
cellular damage. Therefore, our study is designed to determine whether CYP, an
alkylating agent, induces an inflammatory response within the taste sensory system and
the type of taste sensory cells most affected.
Given the potential disruptive effects of chemotherapy, it is important to try to
protect the taste system from the effects of drugs such as CYP. Studies have shown the
sulfhydryl drug, amifostine (AMF), has cytoprotective effects within taste papillae. AMF
was reported to significantly reduce the effects of CYP, e.g., preventing the loss of papillae,
when injected before CYP (Mukherjee et al., 2013; Delay et al., 2019). CYP also
dramatically reduces the population of proliferating cells that replace cells within taste bud
due to their short life spans and high turnover rate (Mukherjee et al., 2013; Cohn et al.,
2010; Chaudhari & Roper, 2010). Pretreatment with AMF protected this critical population
of proliferating cells (Mukherjee et al., 2013). Therefore, a second goal of this study was
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to determine whether the pre-injection of AMF prevents CYP-induced inflammation within
the taste sensory system.
2.2 Methodology & Materials
2.2.1 Ethical Consideration
The animal care and experimental protocol were reviewed and approved by the
Institutional Animal Care and Use Committee of the University of Vermont under the
protocol 14-003. All efforts were made to minimize suffering.
2.2.2 Animals
Male C57BL/6J mice were obtained from Jackson Laboratories

(Stock No:

000664; https://www.jax.org/strain/000664; Bar Harbor, ME, USA) which were housed
and acclimatized in the animal care facility for at least 7 days before perfusion and further
experimental procedures were performed. The animals were typically between 25-30
grams and were housed in groups of 2-4. The mouse colony was maintained on 12/12 hr
light and dark cycles. Food (Purina Chow, Prolab RMH 3000) and water was provided to
the animals ad libitum.
2.2.3 Drugs and reagents
CYP (cyclophosphamide monohydrate, 97%) was obtained from Arcos Organics,
New Jersey, USA. The 0.9% sodium chloride injection, USP was obtained from Hospira
Inc (Lake Forest, Illinois).

AMF (Amifostine-2-(3-Aminopropyl) aminoethyl

phosphorothioate, 97%, Cat no. 1019406) was obtained from (USP reference standard,
Rockville, MD). Lipopolysaccharides from E. coli 0111: B4 was obtained from Sigma
Aldrich (L2630-10MG St. Louis, MO). All the drugs and reagents were freshly prepared
in saline solution before injecting into the animals.
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2.2.4 Dosage
The dose for CYP was chosen using a dose response curve where three different
doses (37.5, 75 and 150) mg/Kg was used. It was observed that a dose of 37.5 mg/kg caused
some difficult to detect damage to taste buds in mice. On the other hand, a dose of
150mg/kg causes nephrotoxicity in mice (Delay et al., 2019; Girard et al., 2011; Vizzard,
2000). Ultimately, a dose of 75mg/kg was chosen, since it has detectable taste-related
changes within the taste buds.
The dose for AMF was based on clinical reports and previous work with mice.
When used as a pretreatment to CYP, 100mg/kg AMF administered subcutaneously has a
protective effect over the taste cells of mice without apparent side effects (Mukherjee et
al., 2013). Previous clinical data suggest high doses can cause numerous side effects
(Adamson et al., 1995). To be able to avoid these potential adverse effects and to be able
to compare our results with previous data, a dose of 100 mg/kg was chosen for this study.
2.2.5 Tissue Collection
The animals for the experiment were randomly assigned to different time points
prior to CYP or AMF injection. Post CYP injection, the animals were perfused at one of
the following time points: 8 hr, 16 hr, 24 hr, 48 hr and 72 hr post injection. At the assigned
time point they were euthanized using sodium pentobarbital. The control group was
injected with saline (1 ml/kg) followed by immediate perfusion and was represented as 0
hr. A group of animals were injected with AMF, 30 minutes prior to CYP injection and
perfused 24hr post injection. In addition, a control group was injected with AMF and
perfused 24 hr post injection. After euthanizing the animals from each group with sodium
pentobarbital, they were perfused with 0.1M phosphate-buffered saline (PBS) mixed with
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heparin, followed by 4% paraformaldehyde mixed with PBS to immediately fixate the
tongue tissues (Electron Microscopy Sciences, PA, USA). The tissues were then soaked in
4% paraformaldehyde solution for about 3 hours. Post paraformaldehyde fixation, the
tongue tissue was transferred to 30% sucrose solution in PBS for at least two days before
blocking them for storage in a cryo-mold using OCT. These were stored at -80o C until
cryosectioning. Tongue tissue was sectioned in a cryostat at 12µm thickness to obtain thin
slices of tongue papillae which were mounted directly on Super-frost Plus glass slides
(Fischer Scientific, MA, USA).
2.2.6 Immunohistochemical labeling
2.2.6.1 Co-labeling TNF-α with PLC. To Co-label TNF-α with PlCb2, tissues
collected after injecting CYP, AMF and saline treatments were thawed and washed in PBS.
Tissue processing was completed in a series of batches of slides. Each batch of tissue
included sections representing at least one animal from each group injected with CYP and
perfused at 0, 8, 16, 24, 48-, and 72-hour post injection. Each batch also included sections
of an animal that was injected with AMF and CYP 30 minutes post AMF, and an animal
that had received AMF alone. The slides were washed in 0.1M PBS before the antigen
retrieval procedure in 10mM sodium citrate for 20 mins at 90 C. The slides were
subsequently allowed to cool down for 40 mins before washing them in 0.1M PBS with
0.3% Triton-X. The slides were then incubated in a permeabilization buffer comprised of
0.1% Saponin (Cat no# SAE0073, Sigma Aldrich, St. Louis, MO, USA), PBS and 0.3%
Triton-X 100 (Cat # T9284, Sigma Aldrich, St. Louis, MO, USA) for an hour.
Subsequently, the slides were blocked using 5% Normal Donkey Serum, 0.1% Saponin
and PBS buffer for 1 hour 30 minutes in room temperature. Primary antibodies against
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TNF-α and PLCβ2 were applied using, goat anti-TNF-α antibody (R&D Systems, Cat no.
AF510NA) and rabbit anti-PLCβ2 antibody (Cat # sc-206, Santa Cruz Biotechnology, Inc,
Dallas, TX, USA) mixed in 5% normal donkey serum solution at 1:75 and 1:500
concentrations, respectively, for 24hrs at 4o C. The slides were rinsed in PBS 0.3% TritonX before applying Alexa Fluor 488 donkey anti-rabbit IgG (Cat #A21206) and Alexa Fluor
546 donkey anti-goat (A11056) secondary antibody (Life Technologies ltd., Rockville,
MD, USA) for 1.5 hours at 1:1000 concentration. The slides were subsequently washed in
0.1 M PBS, incubated in DAPI, a nuclear stain to facilitate cell counting and mounted with
Fluoromount-G (Southern Biotech, Birmingham, AL, USA).
2.2.6.2 Co-labeling TNF-α with SNAP-25. Slides were also labeled to detect TNFα in Type III cells. Type III cells are identified with the biomarker SNAP-25 produced in
rabbit (Cat # S9684, Sigma Aldrich, St. Louis, MO, USA). A similar protocol as the colabeling of TNF-α with PLCβ2 was used to co-label SNAP-25 with TNF-α.
2.2.7 Image analysis and cell counts
Data collection was performed using fluorescence imaging with a Nikon Eclipse
E600 fluorescent microscope with a photometric Cool SNAP EZ camera for image
capturing. The images were captured using SPOT Advanced (Version 5.1) software
keeping the same gain and a relatively similar exposure time. Subsequently, the images
were sharpened, merged, and counted using Adobe Photoshop CS8 and NIH ImageJ
software.
Taste buds on either side of the circumvallate papilla close to the trench were
selected for analysis. A taste bud was selected only if the onion-shaped structure was
maintained from the pore at the trench to the basal region of the bud and the cells were
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oriented along their long axis. Fungiform taste buds were selected only if they had a taste
pore and their cells appeared oriented along their long axis. Cells were labeled PLCβ2 or
SNAP25, TNF-α, and DAPI in red, green and blue, respectively. For each animal, 7-10
taste buds were identified and counted for TSCs for each taste cell marker. Taste buds from
four animals were selected for each time point and AMF condition.
Quantification of each taste bud included counts of total numbers of cells within a
taste bud (DAPI), the total number of cells labeled with either PLCβ2 for Type II or SNAP25 for Type III cells, the number of cells labeled for TNF-α, and the number of cells double
labeled with TNF-α and either PLCβ2 or SNAP-25. To determine the percentage of each
cell type also double-labeled with TNF-α, the total number PLCβ2 or SNAP-25 labeled
cells was then used as the divisor of the cell count co-labeled with TNF-α, and then
multiplied by 100. The proportions obtained are averaged across all four animals at
different treatment conditions. The data obtained were analyzed on GraphPad Prism 8
where a one-way ANOVA was performed to compare treatment groups among each other
to identify significance differences between groups. Tukey’s multiple comparison tests
were then used to identify which groups differed significantly. An alpha of P< 0.01 was
used for all statistical comparisons throughout the experiment.

2.3 Results
Infection-induced inflammation is quite common in taste buds as described by the
presence of pro-inflammatory cytokines (Wang, Zhou, Brand, & Huang, 2007). The
purpose of our study was to detect whether inflammation is induced by CYP in the taste
sensory organ and whether AMF can prevent this inflammation. We found that CYP
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induces a higher expression of TNF-α in taste buds within fungiform and circumvallate
papillae after a single CYP injection and AMF successfully prevents higher expression of
TNF-α in taste buds, when pre-injected.
We had four different sets of data based on differences in the papillae type and the
type of cellular marker labeling the two different types of TSCs. The four sets are Type II
TSCs in fungiform taste buds, Type II TSCs in circumvallate taste buds, Type III TSCs in
fungiform taste buds, and Type III TSCs in circumvallate taste buds. Each set included the
data for the mice at each post injection time point. The data analyses are presented in the
order of (1) total number of cells (DAPI signal), (2) cells labeled as TNF-α, (3) cells labeled
as Type II or Type III, and (4) cells double labeled as a cell type+ TNF-α,
2.3.1. CYP induced expression of TNF-α
2.3.1.1. Type II Cells in Fungiform and Circumvallate Taste Buds.
Fungiform taste buds. The total number of cells (labeled with DAPI) observed in
fungiform taste buds of the six CYP groups did not differ statistically (Figure 1A). The
one-way ANOVA evaluation of the total number of cells labeled with TNF-α per taste bud
showed significant differences in effects of CYP between groups (F (5,18) = 33.20,
P<0.0001; Figure 1C, Figure 2). Tukey’s multiple comparison shows a difference between
8hr versus saline, 16, 48, and 72hr groups (P<0.005). The total TNF-α per taste bud was
higher at 8hr than all the other groups mentioned. A significantly higher number of TNFα was also observed at 24hr than saline, 16, 48 and 72 hr groups of animals administered
CYP (P<0.002). In addition, the one-way ANOVA applied to the number of PLCβ2 labeled
cells (regardless of TNF-α labeling) identified no significant difference in effect of CYP
over the time frame of the experiment (F (5,18) = 0.866, P>0.01; Figure 1B, Figure 2).

43

However, the percentage of Type II cells also exhibiting TNF-α label varied significantly
between mice at each time point (F (5,18) =20.82, P<0.0001; Figure 1D, Figure 2).
Multiple comparison tests indicated that the percent of double-labeled cells were
significantly higher at 8 and 24 hr than observed in saline, 16, 48, and 72 hr time points
(P<0.01).
Circumvallate taste buds. The total number of cells (labeled with DAPI) observed
in circumvallate taste buds of the six CYP groups did not differ statistically and were quite
constant across groups (Figure 3A). The one-way ANOVA evaluation of the total number
of cells labeled with TNF-α showed significant differences between CYP groups (F (5,18)
= 25.39, P<0.0001; Figure 3C, Figure 4). Tukey’s multiple comparison tests showed a
difference in the TNF-α cells between 8hr and 24hr versus saline, 16, 48, 72hr CYP groups
(P<0.0006). The TNF-α cells per taste bud was much higher in animals at 8hr and 24hr
than at 16, 48 and 72 hr CYP groups. In addition, the one-way ANOVA applied to the
number of PLCβ2 labeled cells (regardless of TNF-α labeling) identified no significant
effect of CYP across groups over the time course of the experiment (F (5,18) =0.86, P=0.5;
Figure 3B, Figure 4). However, the percent of Type II cells also exhibiting TNF-α label
varied significantly between groups at each time point (F (5,18) =11.92, P<0.0001; Figure
3D, Figure 4). Multiple comparison tests indicated that the percent of double-labeled cells
were significantly higher at 8 and 24 hr than observed in saline, 16, 48, and 72 hr time
points (P<0.01).
2.3.1.2. Type III cells in Fungiform and Circumvallate taste buds
Fungiform taste buds. Our observations did not show any statistical difference in
the total number of cells (labeled with DAPI) observed in fungiform taste buds of the six
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CYP groups, with cells evenly distributed among each of the six groups (Figure 5A). The
one-way ANOVA evaluation of the average number of cells labeled with TNF-α also
showed no significant difference in the effect of CYP over groups (F (5,18) = 2.136,
P<0.1); Figure 5C, Figure 6). In addition, the one-way ANOVA applied to the number of
SNAP-25 labeled cells (regardless of TNF-α labeling) identified no significant difference
in effect of CYP over the time frame of the experiment (F (5, 18) = 2.403, P<0.1; Figure
5B, Figure 6). The average number of Type III (SNAP-25) cells remained quite constant
throughout all the groups. Similarly, the number of Type III cells exhibiting TNF-α label
did not vary significantly between mice at each time point (F (5,18) =0.7449, P<1; Figure
5D, Figure 6).
Circumvallate taste buds. The total number of cells (labeled with DAPI) observed
in circumvallate taste buds of the six CYP groups did not differ statistically and the average
numbers were quite even (Figure 7A). The one-way ANOVA evaluation of the total
number of cells labeled with TNF-α show significant difference in effect of CYP between
groups, (F (5,18) = 7.398, P<0.001; Figure 7C, Figure 8). Tukey’s multiple comparison
tests identified differences between the 24 hr group and 48 hr (0.001). The total number of
TNF-α per taste bud was considerably higher at 24 hr than 48 hr group. Similarly, a
statistical difference was observed between 8hr and the 48hr CYP group, where the total
TNF-α per taste bud at 8hr was higher than the numbers observed at 48hr (P<0.01). In
addition, the one-way ANOVA applied to the number of SNAP-25 labeled cells (regardless
of TNF-α labeling) identified no significant effect of CYP over the time frame of the
experiment, with an equivalent number of cells across all groups (F (5, 36) =0.1209, P=0.9;
Figure 7B, Figure 8). However, the percent of Type III cells also labeled with TNF-α
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antibody varied significantly between mice at each time point (F (5,18) =5.699, P<0.0001;
Figure 7D, Figure 8). Tukey’s multiple comparison tests indicated that the percent of
SNAP-25/TNF-α positive cells were significantly higher at 24hr than saline and 48hr
groups. A significant difference was also observed between 8hr and 48hr groups, where
the number of Type III cells with TNF-α label at 8hr was higher than at 48hr (P<0.01).
2.3.2. Amifostine
2.3.2.1. Type II (Fungiform, Circumvallate). Fungiform taste buds: The average
number of DAPI labeled cells in the fungiform taste buds did not differ statistically among
the four different groups either injected with saline, CYP-24hr and/or AMF-24hr (Figure
9A). In addition, the one-way ANOVA evaluation of the TNF-α labeled cells (F (3,12) =
25.68, P<0.0001; Figure 9C, Figure 10) detected significant differences among treatment
groups. The mean TNF-α labeled cells per taste bud was significantly higher in the CYP
treated group than saline, AMF and CYP-AMF treated groups (P<0.01). One-way ANOVA
evaluation of PLCβ2 cells (regardless of TNF-α labeling) (F (3,12) = 0.5878, P>0.1; Figure
9B, Figure 10) in the taste buds did not detect any statistical difference among its groups.
The number of PLCβ2 cells were quite constant across groups. However, the percent of
Type II cells double-labeled with TNF-α antibody varied significantly between treatment
groups (F (3,12) = 13.82, P<0.01; Figure 9D, Figure 10). Tukey’s multiple comparisons of
the treatment groups suggest a significantly higher percentage of PLCβ2 and TNF-α
double-labeled cells in the CYP group than in the saline, AMF, and AMF-CYP treatment
groups (all Ps<0.01).
Circumvallate taste buds: The average number of DAPI labeled cells in the
circumvallate taste buds did not differ significantly among different treatment groups
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(Figure 11A). The one-way ANOVA evaluation of the average TNF-α labeled cells in the
circumvallate taste buds exhibit a significant difference among its treatment groups (F
(3,12) =19.52, P<0.01; Figure 11C, Figure 12). Tukey’s multiple comparison tests found a
significantly higher average number of TNF-α cells in the CYP group compared to saline,
AMF, and AMF-CYP groups. Similarly, a one-way ANOVA evaluation of the average
number of PLCβ2 positive cells in the taste buds (regardless of TNF-α labeling) found
significant differences between its treatment groups (F (3,12) = 4.844, P<0.01; Figure 11B,
Figure 12). Tukey’s multiple comparison tests comparing these groups revealed
significantly and unusually higher number of PLCβ2 cells in CYP than in the AMF-CYP
groups. At the same time, the percent of Type II cells co-labeled with TNF-α showed a
significant difference among its groups, (F (3,12) = 16.57, P<0.01; Figure 11D, Figure 12).
Tukey’s multiple comparisons tests detected a significantly higher percentage of doublelabeled cells in the CYP group of animals than the rest of the groups (P<0.001).
2.3.2.2. Type III (Fungiform, Circumvallate). Fungiform taste buds: The average
number of DAPI labeled cells in the fungiform taste buds did not differ statistically among
the four different groups either injected with saline, CYP and/or AMF (Figure 13A). The
one-way ANOVA evaluation of the sum of TNF-α labeled cells in each taste buds showed
no significant statistical difference among its groups (F (3,12) =1.555, P>0.1; Figure 13C,
Figure 14). At the same time, the one-way ANOVA evaluation of SNAP-25 cells in the
taste buds (regardless of TNF-α labeling) indicated no statistical difference (F (3,12) =
1.551, P=0.252; Figure 13B, Figure 14). Also, the percentage of Type III cells exhibiting
TNF-α label did not vary significantly between treatment groups (F (3,12) =0.6582,
P=0.593; Figure 13D, Figure 14).
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Circumvallate taste buds: The average number of DAPI labeled cells in the
circumvallate taste buds did not differ significantly among different treatment groups
(Figure 15A). However, the ANOVA evaluation of the average TNF-α labeled cells in the
circumvallate taste buds showed an overall significant difference among its treatment
groups (F (3,12) =6.838, P<0.01; Figure 15C, Figure 16). We detected a significantly
higher average TNF-α labeled cells in CYP injected group than the AMF group. Similarly,
the one-way ANOVA evaluation of the average SNAP-25 cells in the taste buds (regardless
of TNF-α labeling) show no significant difference between its treatment groups (F (3,12)
= 2.193, P>0.01; Figure 15B, Figure 16). In contrast, the percent of Type III cells labeled
with TNF-α showed a significant difference among treatment groups (F (3,12) =13.17,
P<0.001; Figure 15D, Figure 16). Tukey’s multiple comparisons evaluation showed
significant higher percentage of double-labeled cells in the CYP group compared to the
other groups (P<0.01).
2.4 Discussion
Prior research has pointed both towards a behavioral and a cellular aspect of taste
related dysfunction following administration of CYP. Early research indicated that CYP
induced conditioned taste aversion, a very well-known phenomena of learning where
individuals start avoiding food due to a prolonged nausea during administration of the drug
which is associated with the ingestion of food. Even though the nausea is potentially an
effect of the drug, it quickly gets associated with food. More recently, our lab has identified
the loss of murine taste buds in both fungiform and circumvallate over a period of 16 days
after CYP treatment. We have observed a loss in fungiform taste buds at around 2-4 days
post CYP injection and a later phase in the loss of circumvallate papillae between 8-10
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days post CYP-injection. Our present study has been an extension of the broader concept
to find out if inflammation induces an immediate effect of the administration of CYP. This
corroborates the behavioral study in our lab, which demonstrated bi-phasic increase in taste
threshold at similar times (Mukherjee & Delay, 2011).
Our research supports our hypothesis that CYP induces an inflammatory response.
Our findings suggest CYP induced differential expression of cytokine TNF-α in the taste
buds of both fungiform and circumvallate papillae. CYP is known to have toxic effects
within the taste sensory system and therefore we expected it to induce an inflammatory
response immediately after its injection into the animals.
The expression of cytokines within the taste sensory system is constitutive and is a
normal physiological phenomenon, providing either a protection or having a deleterious
effect (Feng et al., 2012; Hsu, Xiong, & Goeddel, 1995). Cytokines have both paracrine
and autocrine effect over the sensory cells, regulating important taste sensory mechanisms.
We chose TNF-α as a cytokine marker due to its role in chronic inflammation in tissues,
including the taste sensory system, which is induced by NF-kappaB and its ability to
modulate numerous other molecules including cyclooxygenase (cox-2), inducible nitric
oxide (iNOS), other inflammatory cytokines, and chemokines (Aggarwal, 2004; Ahn &
Aggarwal, 2005; Cohn et al., 2010). It is also known to induce cell death within the tissues,
by activating certain downstream cell death signaling pathways.
There are three different types of taste sensory cells, Types I, II, and III, responsible
for taste detection. Our study involved investigating the expression of TNF-α in Type II
and Type III cells after CYP administration but not the Type I cells. Type I cells are salt
taste sensing cells and are difficult to quantify due to its unusual morphology and its
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wrapping around other two types of taste cells, performing its glial like function. Type II
cells are known to express TNF-α constitutively as well as when induced by
lipopolysaccharide administration, whereas no evidence of expression was observed in
Type III cells (Feng et al., 2012). Our study detected the expression of TNF-α in both Type
II and Type III cells in taste buds, even though differentially based on papillae type. Type
II cells were detected in both fungiform and circumvallate taste bud express TNF-α,
whereas Type III cells expressed TNF-α only in the circumvallate taste buds. The presence
of TNF-α in Type III cells suggest that there are signaling pathways present in these cells
to induce an expression of TNF-α.
Earlier work in our lab using TUNEL and caspase-3 assays to investigate cell death
after CYP administration. The TUNEL assay found cells dying at 4 hours, peaking at 6-8
hours, and returning to control levels after 18 hours. On the other hand, caspase-3 signal
began to increase at 8 hours, peaked at 24 hours, and returned to normal levels by 48 hours
post injection. Mukherjee et al. (2017) suggested CYP initially induces cell necrosis
followed by apoptosis within hours after administration. Our study also supports these
earlier findings. The peak expression of the cytokine, TNF-α in Type II cells was observed
at 8- and 24-hour post CYP-injection which coincides with peak times of cell death in taste
buds (Mukherjee et al., 2017). In contrast, increased expression of TNF-α in Type III cells
was only observed 24 hours post injection indicating a late onset of any effect CYP could
have over these cells. It may indicate the expression of pro-inflammatory cytokine TNF-α
could have a role in cell death.
Our findings suggest that even a single administration of CYP can have a profound
effect on the taste system within hours of administration. For example, the data for each of
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our animals are based on a sample from a 12-um thick section typically with 15-20 DAPI
labeled cells. If one assumes an individual taste bud is comprised of about 100 TSCs, then
about 30 cells are of Type II and 10 cells are Type III. The data of our saline injected mice
indicated about 20 percent of Type II TSCs in both fungiform and circumvallate taste buds
also expressed TNF-α. Extended to our hypothetical bud of 100 cells, this means roughly
6 TSCs out of 30 in the taste bud. In contrast, CYP injected animals exhibited about 80
percent of Type II cells with TNF-α expression at 8- and 24-hours post injection. This
suggests about 24 of 30 TSCs in the hypothetical taste bud showed increased TNF-α
expression at these post injection periods. Similarly, saline injected mice in Type III cells
only have about 20 percent of their TSC population express TNF-α, which stands roughly
at around 2 cells per taste bud. On the contrary, the CYP injected animals have an
expression of TNF-α in 6 TSCs out of 10 Type III cells in the entire taste bud. Extending
these estimates, it is easy to see CYP-induced inflammation could inevitably have a
significant impact over the entire taste system. Subsequent pro-inflammatory responses in
the TSCs could lead to severe long-term implications in the taste sensory system of
chemotherapy patients possibly resulting in taste sensory loss.
It is unlikely that saline could induce over-expression of TNF-α in the TSCs
evaluated in this experiment. Saline was used as the vehicle of drug administration for both
CYP and AMF. If saline is responsible for the TNF-α over-expression, then the effect
would be visible in both CYP as well as AMF injected animals. However, the reduction of
TNF-α in the TSCs pre-injected with AMF argue that TNF overexpression by saline would
be a highly unlikely event.
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We also analyzed the average number of cells present in taste buds which was DAPI
labeled, corresponding all the cells in taste buds and the average Type II, Type III cells in
the taste buds. As per our earlier study on cell death assays, we expected to see some
decline in the overall number of cells in taste bud. We did see some decline in Type II cells
in both fungiform and circumvallate taste buds at around 72-hour post injection, though it
wasn’t significantly different from the control groups. Similar observation was made for
Type III cells in circumvallate papillae with no statistical difference. It is possible that the
post-mitotic immature Type IV cells have already migrated into the taste bud which rapidly
mature and differentiate into different types of taste sensory cells to replace the dying cells
within the taste bud. The lack of decline in the overall DAPI labeled cells could also be the
result of the counter expression of anti-inflammatory cytokines such as IL-10 in taste
sensory cells. This could regulate the deleterious effect of pro-inflammatory cytokine TNFα, which has the potential to induce cell death (Feng et al., 2014).
The second goal of our study was to determine if AMF could prevent an
inflammatory response in taste sensory cells against the effect of CYP. AMF is a clinically
proven drug, effective in protecting normal cells against radiation or chemotherapeutic
effect. Clinical studies using AMF in patients undergoing cisplatin or CYP treatment to
protect against chemotherapeutic induced damage of normal tissue, have been well
documented in patients with ovarian carcinoma and have been effective in recovering a
steady platelet count and preventing peripheral neuropathy (Rose, 1996). Importantly,
AMF does not interfere in the efficacy of chemotherapy, vital to its use in patients with
cancer (Capizzi, 1996).
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Use of AMF in our study is warranted in view of its earlier use in patients to treat
CYP induced hemorrhagic cystitis, a form of inflammation, an occurrence after bone
marrow transplantation (Haldar, Dru, & Bhowmick, 2014; Srivastava et al., 1999).
Extensive laboratory research on this drug has proved its efficacy in protecting taste
sensory cells as well (Mukherjee et al., 2013). The mechanism of action of AMF suggests
that it preferentially protects normal cells but not tumor cells due to its ability to
differentiate the pH of these cells. This drug only metabolizes into its active compound in
cells in which alkaline phosphatase is available in sufficient quantities (Grdina et al., 2000).
To our knowledge, no previous study has been conducted to investigate if AMF can
block inflammatory cytokine TNF-α expression in the taste sensory system. We
administered AMF at 100mg/Kg, pre-injecting it 30 minutes prior to CYP injection. The
dosage administered was significantly less than what is usually utilized in patients with
ovarian carcinoma (Rose, 1996). Our results indicate AMF has a protective effect in
preventing CYP-induced inflammation, as evident by its ability to prevent increased
expression of TNF-α in different taste sensory cell types within both the circumvallate and
fungiform papillae. It was more effective in preventing an inflammatory response within
the circumvallate than the fungiform papillae. The Type II cells in both the fungiform and
circumvallate papillae showed a decline in expression of TNF-α in animal groups preinjected with AMF than when only injected with CYP (Figures 10 & 12) On the other hand,
Type III cells showed a greater decline in the inflammatory response within the
circumvallate taste buds than in fungiform taste buds.
AMF seems to be a promising drug in preventing the inflammatory response within
the taste cells. AMF’s mode of action is to act as a scavenger to get rid of free radicals
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produced during cellular stress and damage. It is quite possible these free radicals in cells
are involved in triggering a cytokine response and inflammation. The metabolized active
compound of AMF, possibly gets rid of the free radicals in cells to prevent the signaling
mechanism to initiate and prevent an inflammatory response in cells.
Our study involves a holistic approach towards research on chemotherapy induced
inflammation and ways to prevent it by using another drug. The cytokine we chose to
investigate is well documented within the taste buds which performs functions such as cell
proliferation and growth. Any unwanted upregulation can have deleterious consequences
in the taste sensory system. This research is only the beginning of exciting new possible
work that could be performed in the future to understand more about the consequences
cytokines could have over the taste sensory system. Possible investigation into the other
commonly found cytokines in the taste buds could reveal more about its functions in
regulating the taste sensory system. Future studies could be conducted to corroborate our
work by conducting conditioned knockout of the TNF-α receptor gene to visualize if the
effect was due to the expression of TNF-α or other factors could be involved in it.
Understanding inflammation is crucial for the cancer patients who regularly undergo
chemotherapy to experience chemotherapy induced taste dysfunction so that antiinflammatory cytokine therapy could be developed to reduce or ameliorate the effect of
CYP induced taste related dysfunction.
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CHAPTER 3: CONCLUSION AND FUTURE DIRECTIONS

3.1 CONCLUSION
Our research expands on a long-standing work started several years earlier in our
lab on the effects of the chemotherapy drug, cyclophosphamide (CYP) on the taste system.
Our earlier studies have shown an immediate effect of CYP (75mg/Kg) injection in animals
which results in cell death peaking 8 hours post injection followed by another phase of cell
death peaking at 24 hours post injection. This had initiated a cascade effect resulting in a
biphasic deficit in taste function at 2-4 days and 8-12 days post CYP injection, the timing
of which is associated with a loss in taste buds both in fungiform and circumvallate
papillae.
Our present study tries to unravel some of the initial effects such as inflammation
occurring immediately after CYP administration, that could be responsible for the toxicity
induced cellular damage. For this work, we decided to investigate the presence of TNF-α
in Type II and Type III taste sensory cells. TNF-α is a pro-inflammatory cytokine produced
by immune cells such as macrophages, lymphocytes and monocytes inducing an
inflammatory reaction to any abnormalities within the cells. It is also important in
regulating multiple physiological processes such as differentiation, proliferation and cell
survival. Any dysregulation in its normal cellular expression could affect multiple
physiological processes and therefore we decided to investigate TNF-α expression in its
role as an inflammatory marker after CYP administration.
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Our study found expression of the cytokine TNF-α in the Type II and Type III taste
sensory cells in taste buds of both circumvallate and fungiform papillae. Type II cells were
most affected as we found a higher percentage of double-labeled cells in both circumvallate
and fungiform papillae after CYP injection. Similar to previous research in which LPS was
used to induce inflammation in the taste system of mice, there was increased expression of
TNF-α in Type II cells after CYP injections, suggesting that one of the effects of CYP
results in activating the signaling pathways for TNF-α in these cells. Our study also
identified the presence of TNF-α in Type III cells which previously was not identified.
Perhaps, CYP induces or activates another pathway which has not been identified yet.
Our second goal for this study dealt with the use of AMF, a sulfhydryl drug
previously found to have cytoprotective effects against chemotherapy and radiotherapy in
both laboratory and clinical settings. It is an FDA approved, widely used cytoprotective
agent. Our investigation was to determine if pre-injection of AMF could prevent an
inflammatory response within the Type II and Type III taste sensory cells. Indeed, we
found a decline in cytokine TNF-α expression in both types of taste sensory cells after CYP
administration. The decline in the expression of TNF-α was much more distinctive in the
circumvallate than in the fungiform papillae. The cytokine response is due to the free
radicals generated due to the toxicity caused by CYP. The free radicals are known to cause
damage to the DNA by cross linkages in the single stranded DNA and amifostine likely
helps to reduce the free radicals formed.
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3.2 FUTURE DIRECTION
3.2.1 Does CYP induced inflammation in taste sensory cells affect the Ki67 labeled
proliferating cells
The effect that CYP has over cell proliferation over time within the taste buds is
quite well studied in our lab. Observations made over a period of 16 days after CYP
injection has shown a sharp decline in Ki67 positive cells (a cell cycle marker) within the
basal layer of the taste bud up to 6 days post injection in both fungiform and circumvallate
papillae (Delay et al., 2019; Mukherjee et al., 2013). This clearly suggests the taste sensory
cell proliferation and replacement cycle is affected post CYP injection. Subsequent study
to see the effects of CYP administered by dose fractionation has also indicated a
suppression in Ki67 positive cells in the taste buds which does not completely recover until
day 10 post injection (Delay et al., 2019).
In future, we could design a long-term study over a period of 16 days for both a
single CYP injection and dose fractionation experiment to investigate the expression of
pro-inflammatory cytokines as well as anti-inflammatory cytokines. This could bring to
light, exactly if long term expression of pro-inflammatory cytokine could possibly suppress
the cell proliferation cycle over an extended period. The purpose of looking into the antiinflammatory cytokines would provide some clues into if their expression is a mode
utilized by the taste sensory system to protect itself against toxicity of the drug as well as
the release of pro-inflammatory cytokines.
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3.2.2 Characterizing the specific subset of Type II cells affected by CYP induced
over-expression of TNF-α?
In our current study we were able to determine that the Type II cells expressed the
cytokine TNF-α in both fungiform and circumvallate taste buds. This peak expression was
detected at 8 and 24-hour post-CYP injection. We conducted our study using only PLCβ2
to label all of the Type II cells. This leaves the study incomplete in terms of specifically
identifying the subsets of Type II cells which could be most affected. In her earlier research,
Wang had noticed only a subset of Type II cells expressing TNF-α, specifically Type II
cells with T1R3 receptors. T1R3 receptors form heterodimer with T1R1 or T1R2 to detect
umami or sweet substances. They have speculated the expression of TNF-α is primarily to
regulate signaling pathways involved in these basic taste detection (Feng et al., 2012). We
expect the primary function of TNF-α is to regulate taste pathways and may be found in
only a subset of Type II cells.
For example, one immunohistochemistry experiment could be setup by using
antibody labels against TNF-α, PLCβ2 and gustducin to determine if both subsets of cells
are affected by CYP-induced inflammation. Gustducin is known for labeling a specific
subset of Type II cells that detect bitter (Yang, Tabata, Crowley, Margolskee, & Kinnamon,
2000). The experiment could be conducted over a period of 72 hours along with saline
control animals. Any co-expression of TNF-α with gustducin and PLCβ2 would suggest
the subset of Type II cells are affected indicating its relevance and importance in regulating
in all subsets of Type II cells. Conversely, a lack of co-expression would suggest a different
subset of Type II cells are expressing TNF-α.
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3.2.3 Does chemotherapy induced inflammation have any effect over the nerve
endings adjacent to the taste buds?
Taste sensory disorders due to inflammatory infection has been well documented
in previous work and patient accounts (Mann, 2002). A recent study suggested that LPS
induced infection activates the interferon pathway in mice (Wang et al., 2007). Loss of
taste buds along with rapid expression of cytokines IL-6 or TNF-α have also been observed
in mice with inflammation (Cohn et al., 2010). All the above studies have suggested an
adverse effect of inflammation on the functioning of the taste sensory system. Our lab has
previously conducted behavioral studies in mice to observe taste acuity in umami taste after
CYP-injection, showing a biphasic response between 2-4- and 8-12-days post injection.
Significant losses in sensitivity to umami, salt and sucrose substances were observed
(Mukherjee et al., 2013, 2017).
From our research work, we were able to identify the type of taste cells, most
affected or inflamed due to chemotherapy. We found Type II cells in fungiform and
circumvallate papillae to be inflamed as well as Type III cells in the taste buds of
circumvallate papillae. The possible reasons for the elevation in taste detection thresholds
for the basic tastes we have studied could be due the inflammation in different types of
taste cells at an early stage due to chemotherapy resulting in an early cell death and loss of
taste buds at a later stage.
It would be worthwhile to investigate any effect inflammation has over the nerve
endings adjacent to the taste buds. It is also possible that encoding processes may be
adversely affected by CYP-inflammation. Immunohistochemistry experiments could be
setup using PGP 9.5 to label the nerve endings in control versus CYP injected animals to
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see if CYP causes damage to the nerve endings that corresponds to the immediate effect of
inflammation.
3.2.4 What are the other different types of cytokines expressed in taste buds due to
chemotherapy induced inflammation?
This is an important study to identify other different types of cytokines that might be
released by the taste buds due to chemotherapy administration. As I mentioned repeatedly
in my earlier sections, the Wang laboratory has determined the presence of multiple pro
and anti-inflammatory cytokines in the taste buds activated by the administration of LPS.
The expression of both pro and anti-inflammatory cytokines indicates regulation of
physiological consequences within taste buds. The anti-inflammatory cytokines could be a
result of the over-expression of pro-inflammatory cytokines in the taste sensory system.
Similar in-situ or immunohistochemistry experiments could be setup to identify the
presence of other cytokines such as IFN, IL-6 or IL-10 co-expressed in different types of
taste cells. Most of our studies have investigated Type II and Type III cells in taste buds
because quantifying Type I cells are difficult. But it would be worthwhile if we could
devise methods to identify the expression of cytokines in Type I cells as well as it has
important glial like properties and would be crucial to see if its overall function in
maintaining its function in taste buds are affected or not.
3.2.5 Does dose fractionation have differential effect in the expression of cytokines
in taste buds?
Future studies could include working with dose fractionation of chemotherapy
drugs and observing the inflammatory effect it could have over the taste buds. Past research
on single CYP administration versus dose fractionation of CYP on mice have resulted in
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prolonged suppression of cell proliferation in mice after a dose fractionation regime.
Fractionated doses also had a greater effect on mature cells by reducing its overall number
in taste buds (Delay et al., 2019).
A similar dose fractionation immunohistochemistry study could be performed to
investigate the expression of cytokines in taste buds and quantify the overall number of
cells present in the taste buds in each group at different time points throughout the
experiment compared to a single injection in mice. At the same time, qPCR could also be
performed within each group of animals to quantify the level of expression in different
taste sensory cell type within each group in dose fractionated CYP animals versus single
CYP injection animals.
3.2.6 What is the basis of the TNF-α expression in Type III cells?
Prior research on the localization of cytokines, especially TNF-α, was unable to
detect them in Type III cells. They were only localized to a specific subset of Type II
cells (Feng et al., 2012). Our research determined the presence of TNF-α in Type III
SNAP-25 labeled cells. It could indicate the presence of another signaling pathway
distinct from Type II cells activating downstream inflammatory pathway, involved in
some regulatory mechanism in Type III taste sensory cells.
It would be worthwhile to identify the cell signaling pathway involved in Type III
taste sensory cells within the taste buds using immunohistochemistry and
immunofluorescent proteins. These methods may help to localize some possible receptors
involved in detecting CYP as a ligand activating downstream signaling pathways and
visualizing it under the microscope. Another method that could be used would be western
blot. For example, to detect tyrosine phosphorylated protein that could be possibly
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involved in the signaling pathway, we could run lysate and detect it primary and
secondary antibody against those proteins.
3.3 Summary
Our study is quite important in addressing taste related disorders patients
encounter when undergoing chemotherapy on a regular basis. It is vital to the survival
and recovery of these patients from cancer, lessening the persistent suffering they face.
Our study simply deals with one of the many factors associated with chemotherapy
treatment. We have had promising results in identifying potential deleterious effects of
CYP on taste buds that has resulted in broadening our curiosity and posing new questions
which could be investigated. At the same time our Amifostine findings bring new light
about the efficacy of this drug in reducing inflammation in the taste sensory system.

62

FIGURES

DAPI cells in Fungiform

Average PLC in Fungiform
4

PLC+cells/taste bud

DAPI/taste bud

20
15
10
5
0

Saline

8

16

24

48

3
2
1
0

72

Hours

Saline

8

16

Average TNF in Fungiform

***

3
2
1
0

Saline

8

72

PLC and TNF

****

4

48

100
%TNF+/PLCb2 cells

TNF+ cells/taste bud

5

24

Hours

16

24

48

80

****

60
40
20
0

72

Hours

****

Saline

8

16

24

48

72

Hours

P**** <0.0001
P***<0.001
Figure 1: Type II cells in fungiform taste buds. Top left to right: A) The bar graph
illustrates the total number of cells per taste bud labeled in DAPI remained constant
across 72 hours. B) Mean number of PLCβ2 labeled cells per taste bud in mice over a
period of 72 hours. Bottom left to right: C) Bar graph indicates the mean number of TNFα positive cells per taste bud in mice after CYP was administered showed peak responses
at 8 and 24 hours post CYP-injection in mice. D) The line graph illustrates the mean %
TNF-α positive cells co-labeled with PLCβ2, peaked at 8 and 24 hours in mice over a
period of 72 hours, administered CYP (n/group=4).
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Figure 2. Visualization of Type II cells in fungiform taste buds from mice at 0, 8, 16,
24, 48, and 72 hours post CYP injection. Columns A, B, C show isolated taste buds
labeled with PLCβ2 (Green), TNFα (Red), and cells co-labeled with TNFα and PLCβ2,
respectively. TNFα expression peaks at 8 hours and 24 hours post-injection. The
graphical data show a peak inflammatory response at 8 hr and 24 hr, respectively
(n/group=4; scale bar = 20μm).
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Figure 3: Type II cells in circumvallate taste buds. From top left to right: A) The bar
graph illustrates the total number of cells per taste bud labeled with DAPI remained
constant across 72 hours. B) The mean number of PLCβ2 labeled cells per taste bud in
mice over a period of 72 hours. Bottom left to right: C) Bar graph indicates the mean
number of TNF-α positive cells per taste bud in mice after CYP was administered
showed peak response at 8 and 24 hours post CYP-injection in mice. D) The line graph
illustrates the mean % TNF-α positive cells co-labeled with PLCβ2, peaked at 8 and 24
hours in mice over a period of 72 hours after administered CYP (n/group=4).
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Figure 4. Visualization of Type II cells in circumvallate taste buds from mice at 0, 8,
16, 24, 48, and 72 hours post CYP injection. Column A shows a composite image of
taste buds in a circumvallate trench (CV), showing both TNF-α and PLCβ2 merged.
Columns B, C, D show isolated taste buds labeled with TNF-α (Red), PLCβ2 (Green),
and cells co-labeled with TNF-α and PLCβ2, respectively. TNF-α expression peaks at 8
hours and 24 hours post- injection. The graphical data show a peak inflammatory
response at 8 hr and 24 hr, respectively (n/group=4; scale bars = 20μm).
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Figure 5: Type III cells in fungiform taste buds. From top left to right: A) The bar
graph illustrates the total number of cells per taste bud labeled with DAPI remained
constant across 72 hours. B) The mean number of PLCβ2 labeled cells per taste bud in
mice over a period of 72 hours. Bottom left to right: C) Bar graph indicates the mean
number of TNF-α positive cells per taste bud in mice after CYP was administered which
showed no difference in response among its groups. D) The line graph illustrates the
mean % TNF-α positive cells co-labeled with SNAP-25 in mice. This peaked (P > 0.05)
at 8 hours after administered CYP (n/group=4).
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Figure 6. Visualization of Type III cells in fungiform taste buds from mice at 0, 8,
16, 24, 48, and 72 hours post CYP injection. Columns A, B, C show isolated taste buds
labeled with SNAP-25 (Green), TNF-α (Red), and cells co-labeled with TNF-α and
SNAP-25, respectively. TNF-α expression does not show any significant difference
among each of the groups post-CYP injection. The graphical data show a curve at 8 hours
post CYP-injection which flattens at 72 hours (n/group=4; scale bar = 20μm).
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Figure 7: Type III cells in circumvallate taste buds. From top left to right: A) The
bar graph illustrates the total number of cells per taste bud labeled in DAPI remaining
constant across 72 hours. B) Total SNAP25 labeled cells per taste bud in mice over a
period of 72 hours. Bottom left to right: C) Bar graph indicates the mean number of
TNF-α positive cells per taste bud in mice after CYP was administered showed peak
responses at 8 and 24 hours compared to 48 hours post CYP-injection in mice. D) The
line graph illustrates the mean % TNF-α positive cells co-labeled with SNAP25, peaked
at 24 hours post CYP-injection in mice after administered CYP (n/group=4).

69

Figure 8. Visualization of Type III cells in circumvallate taste buds from mice at 0,
8, 16, 24, 48, and 72 hours post CYP injection. Columns A, B, C show isolated taste
buds labeled with TNF-α (Red), SNAP-25 (Green), and cells co-labeled with TNF-α and
SNAP-25, respectively. TNF-α expression peaks at 24 hours post- injection. The
graphical data show a peak inflammatory response at 24 hr (n/group=4; scale bar =
20μm).
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Figure 9: Type II cells in fungiform taste buds in different CYP and AMF treatment
groups. From top left to right: A) The bar graph illustrates total DAPI labeled cells per
taste bud in mice administered saline, CYP, AMF and AMF-CYP remained constant
across groups. B) Mean number of PLCβ2 labeled cells per taste bud in saline, CYP,
AMF and AMF-CYP mice remained constant across treatment groups. Bottom left to
right: C) Bar graphs show the mean number of TNF-α positive cells per taste bud in
mice after CYP was administered showed peak responses than saline, AMF and AMFCYP groups. D) The mean % TNF-α positive cells co-labeled with PLCβ2 show
significantly higher responses in CYP injected groups compared to saline, AMF and
AMF-CYP groups (n/group =4)
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Figure 10. Immunohistochemical assays showing Type II cells in fungiform taste
buds from a saline injected mouse, an AMF treated mouse, a CYP treated mouse
and an AMF pretreated-CYP mouse. Columns A, B, and C show isolated taste buds
labeled with PLCβ2 (Green), TNF-α (Red) and co-label of TNF-α and PLCβ2,
respectively. Graphs show less TNF-α expression in AMI pretreated-CYP mice than in
CYP-treated mice at 24 hr post injection (n/group=4; scale bar = 20μm).
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Figure 11: Type II cells in circumvallate taste buds in different CYP and AMF
treatment groups. From top left to right: A) The bar graph illustrates total DAPI
labeled cells per taste bud administered saline, CYP, AMF and AMF-CYP mice remained
constant across groups. B) Mean number of PLCβ2 labeled cells per taste bud in saline,
CYP, AMF and AMF-CYP mice remained constant across treatment groups. Bottom left
to right: C) Bar graphs show the number of TNF-α positive cells per taste bud in mice
after administered with CYP showed peak response compared to AMF and AMF-CYP
groups. D) Mean % TNF-α positive cells co-labeled with PLCβ2 was significantly higher
in the CYP injected group compared to AMF and AMF-CYP groups (n/group=4)
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Figure 12. Immunohistochemical assays showing Type II cells in circumvallate taste
buds from a saline injected mouse, an AMF treated mouse, a CYP treated mouse
and an AMF pretreated-CYP mouse. Column A shows the circumvallate trench with
TNF-α labeling (Red), PLCβ2 labeling (Green) and DAPI nuclear stain (Blue) co-labeled.
Columns B, C, and D show isolated taste buds labeled with TNF-α, PLCβ2, and co-label
of TNF-α and PLCβ2, respectively. Graphs show less TNF-α expression in AMI
pretreated-CYP mice than in CYP-treated mice at 24 hr post injection (n/group=4; scale
bars = 20μm).
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Figure 13: Type III cells in fungiform taste buds in different CYP and AMF
treatment groups. From top left to right: A) The bar graph illustrates the total number
of DAPI labeled cells per taste bud in mice administered saline, CYP, AMF and AMFCYP remained constant across groups. B) The mean number of SNAP-25 labeled cells
per taste bud in mice administered saline, CYP, AMF, or AMF-CYP remained constant
across treatment groups. Bottom left to right: C) Bar graphs showing significantly
higher number of TNF-α positive cells per taste bud in mice administered CYP compared
to AMF and AMF-CYP groups. D) Mean % TNF-α positive cells co-labeled with SNAP25 show a significantly higher response in the CYP injected group compared to saline,
AMF and AMF-CYP groups (n/group=4)
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Figure 14. Immunohistochemical assays showing Type III cells in fungiform taste
buds from a saline injected mouse, an AMF treated mouse, a CYP treated mouse
and an AMF pretreated-CYP mouse. Columns A, B, and C show isolated taste buds
labeled with SNAP-25 (Green), TNF-α (Red) and co-label of TNF-α and SNAP-25,
respectively. Graphs show less TNF-α expression in AMI pretreated-CYP mice than in
CYP-treated mice at 24 hr post injection (n/group=4; scale bar = 20μm).
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Figure 15: Type III cells in circumvallate taste buds in different CYP and AMF
treatment groups. From top left to right: A) The bar graph illustrates total DAPI
labeled cells per taste bud in mice administered saline, CYP, AMF and AMF-CYP
remained constant across groups. B) The mean number of SNAP-25 labeled cells per
taste bud in saline, CYP, AMF and AMF-CYP mice remained constant across treatment
groups. Bottom left to right: C) Bar graphs show the number of TNF-α positive cells per
taste bud in mice after administered with CYP showed peak response compared to saline,
AMF and AMF-CYP groups. D) Mean % TNF-α positive cells co-labeled with SNAP-25
in mice was significantly higher in CYP injected groups compared to saline, AMF and
AMF-CYP groups (n/group=4)

77

Figure 16. Immunohistochemical assays showing Type III cells in circumvallate
taste buds from a saline injected mouse, an AMF treated mouse, a CYP treated
mouse and an AMF pretreated-CYP mouse. Columns A, B, and C show isolated taste
buds labeled with SNAP-25 (Green), TNF-α (Red), and co-label of TNF-α and PLCβ2,
respectively. Graphs show less TNF-α expression in AMI pretreated-CYP mice than in
CYP-treated mice at 24 hr post injection (n/group=4; scale bar = 20μm)
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